25th SAPA Annual Conference

Advancing Pharmaceutical and Biotechnology Development through Global Collaboration

Challenges and Opportunities

September 29 and 30, 2017

DoubleTree by Hilton
Somerset Hotel and Conference Center
200 Atrium Drive
Somerset, NJ 08873, USA
Dear SAPA Members and Friends,

On behalf of the Sino-American Pharmaceutical Professionals Association (SAPA), I would like to welcome you to SAPA’s 25th SAPA Annual Conference. In this one and a half day event, 70 plus distinguished speakers and panelists will share their views and address issues around the theme of “Advancing Pharmaceutical and Biotechnology Development through Global Collaboration: Challenges and Opportunities”. The expanded sessions for this conference cover all fields in the pharma and biotech industries including:

- R&D, featuring Immuno-oncology
- Breakthrough therapies and their applications
- Beyond R&D
- IP protection, licensing, enforcement, and challenges in business strategies in pharmaceutical and biotech industries
- Business development and licensing
- Global collaboration with outsourcing - impact on the pharma landscape
- The 2nd SAPA Annual Chinese CEO Forum – Stories Beyond the News
- Pharmaceutical investment
- Innovation project road show
- Career development

During the past year, it has been my great pleasure and honor to serve as the President of SAPA. I would like to take this opportunity to thank our members, volunteers, sponsors and friends. With your participation, support and significant contributions, we have been able to promote SAPA to a higher level in fulfilling its missions. I am looking forward to working with all of you to continue SAPA’s 24 year tradition of promoting the advancement of pharmaceutical science and biotechnology, and scientific exchange and business cooperation between US and China.

Take full advantage of this conference: expand your knowledge, network with global experts from across the globe and the pharmaceutical industry, make new friends, discover the services of our corporate sponsors, and explore interesting new career opportunities.

Sincerely,

Lei Tang, PhD
SAPA President
& 25th SAPA Annual Conference Chair
### 25th SAPA Annual Conference Program at a Glance

#### Friday, September 29, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 1:00 pm</td>
<td>Registration</td>
<td>Lobby</td>
</tr>
<tr>
<td>1:00 – 2:40 pm</td>
<td>Plenary Session 1: Life Science Landscape and Regulatory Reform in the US and China</td>
<td>Ballroom West &amp; Center</td>
</tr>
<tr>
<td>3:00 – 5:30 pm</td>
<td>Parallel Session A: Pharma Investment Forum</td>
<td>Ballroom West &amp; Center</td>
</tr>
<tr>
<td>3:00 – 5:30 pm</td>
<td>Parallel Session B: Global Collaboration with Outsourcing - Impact on Pharma Landscape</td>
<td>Ballroom East</td>
</tr>
<tr>
<td>2:30 – 5:30 pm</td>
<td>Job Fairs</td>
<td>Tuscany</td>
</tr>
<tr>
<td>6:00 – 8:00 pm</td>
<td>SAPA VIP Reception (by invitation only)</td>
<td>Mirabelle</td>
</tr>
</tbody>
</table>

#### Saturday, September 30, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 – 8:45 am</td>
<td>Registration</td>
<td>Lobby</td>
</tr>
<tr>
<td>8:45 am – 12:00 pm</td>
<td>Plenary Session 2: Advancing Pharmaceutical and Biotechnology Development</td>
<td>Ballroom</td>
</tr>
<tr>
<td></td>
<td>(SAPA President and EC election results will be announced at 10:10 am before the coffee break)</td>
<td></td>
</tr>
<tr>
<td>12:00 – 1:00 pm</td>
<td>Lunch</td>
<td>Mirabelle</td>
</tr>
<tr>
<td>1:00 – 3:00 pm</td>
<td>Parallel Session C: Business Development Forum</td>
<td>Ballroom East</td>
</tr>
<tr>
<td>1:00 – 4:30 pm</td>
<td>Parallel Session D: Regulatory: Breakthrough Therapy and Its Applications</td>
<td>Ballroom Center</td>
</tr>
<tr>
<td>1:00 – 4:30 pm</td>
<td>Parallel Session E: Scientific Session: Immuno-Oncology</td>
<td>Ballroom West</td>
</tr>
<tr>
<td>1:00 – 5:30 pm</td>
<td>Parallel Session F: 2017 SAPA Startup-Venture Summit – Where Innovation Meets Capital</td>
<td>Room 158</td>
</tr>
<tr>
<td>1:00 – 5:30 pm</td>
<td>Parallel Session G: Career Development Session: The “Yin” and “Yang” of Career Development</td>
<td>Room 166</td>
</tr>
<tr>
<td>3:30 – 5:30 pm</td>
<td>Parallel Session H: The 2nd SAPA Annual Chinese CEO Forum – Stories Beyond the News</td>
<td>Hillsborough*</td>
</tr>
<tr>
<td>1:00 – 4:00 pm</td>
<td>Parallel Session I: Beyond R&amp;D: Commercialization and Marketing in Pharmaceutical Industry</td>
<td>Princeton*</td>
</tr>
<tr>
<td>1:00 – 5:00 pm</td>
<td>Parallel Session J: IP Protection, Licensing, Enforcement, or Challenge as Business Strategies in Pharmaceutical and Biotech Industries</td>
<td>Bridgewater*</td>
</tr>
<tr>
<td>3:00 – 3:15 pm</td>
<td>Afternoon Coffee Break</td>
<td></td>
</tr>
<tr>
<td>5:30 – 6:30 pm</td>
<td>SAPA Reception and Annual Gala Dinner</td>
<td>Mirabelle</td>
</tr>
<tr>
<td>6:30 – 9:00 pm</td>
<td></td>
<td>Ballroom</td>
</tr>
</tbody>
</table>

*These meeting rooms are on the 2nd floor
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greeting Message from the SAPA President</td>
<td>2</td>
</tr>
<tr>
<td>Annual Conference Program At a Glance</td>
<td>3</td>
</tr>
<tr>
<td>About SAPA</td>
<td>5</td>
</tr>
<tr>
<td>SAPA Events – A Year in Review 2016-2017</td>
<td>10</td>
</tr>
<tr>
<td>Conference Program</td>
<td>13</td>
</tr>
<tr>
<td>Speaker and Panelist’s Biography</td>
<td>29</td>
</tr>
<tr>
<td>SAPA Service Excellence Award</td>
<td>45</td>
</tr>
<tr>
<td>2017 SAPA Scholarship &amp; Excellence in Education for Life Sciences</td>
<td>46</td>
</tr>
<tr>
<td>2017 SAPA-Hisun Graduate Travel Grant</td>
<td>47</td>
</tr>
<tr>
<td>SAPA Corporate Sponsors and Media Partners</td>
<td>48</td>
</tr>
</tbody>
</table>
SAPA MISSION

- To promote the advancement of pharmaceutical science and biotechnology
- To make contributions benefiting public health education
- To promote scientific exchange and business cooperation between US and China
- To foster the career growth of pharmaceutical and biomedical professionals

INTRODUCTION TO SAPA

SAPA was founded in 1993 in the US as a non-profit organization and since then has grown rapidly and become one of the most active and well-recognized professional organizations in the US with a membership base of over 4,000. SAPA is headquartered in the Greater New York area (NJ/NY/CT) with six regional chapters (SAPA-NE in New England, SAPA-GP in Greater Philadelphia, SAPA-CT in Connecticut, SAPA-DC in Greater Washington DC area, SAPA-MW in Midwest area, and SAPA-West in West Coast), and one chapter in China. SAPA members are engaged in drug discovery, pre-clinical & clinical development, manufacturing, regulation, marketing, and distribution of pharmaceuticals and biotech therapeutic products. To fulfill its missions, each year SAPA and its regional chapters organize and sponsor many events including the SAPA annual conference, scientific symposia, seminars, workshops, and social activities both in the U.S. and China. These events have been supported and sponsored by many organizations, including major pharmaceutical, biotech and CRO companies as well as many Bio-Parks and Development Zones in China.
SAPA ORGANIZATION STRUCTURE

- **SAPA Executive Council (EC):** President, President-Elect, Immediate-Past-President, Executive Vice President, Vice Presidents, General Secretary, EC Members, and Standing Department Heads. Conducting SAPA daily operations, organizing SAPA events and activities.

- **SAPA Board of Directors (BD):** BD Chair and BD Members including SAPA President and Immediate-Past-President. Setting up policies and regulations, nominating and approving SAPA officers, and guiding SAPA direction.

- **SAPA Advisory Committee (AC):** Chaired by SAPA Immediate-Past-President and over 20 AC Members. Advising, guiding and supporting.

SAPA LOCATIONS

- SAPA Headquarters: New Jersey, USA
- SAPA-CT (Connecticut Chapter): Connecticut, USA
- SAPA-DC (Greater Washington DC Chapter): Greater Washington DC areas, USA
- SAPA-GP (Greater Philadelphia Chapter): Philadelphia and other Pennsylvania areas, USA
- SAPA-MW (Mid-West Chapter): Illinois and Indiana areas, USA
- SAPA-NE (New England Chapter): Boston and New England areas, USA
- SAPA-WEST (West Chapter): California, USA
- SAPA-China: China
President
Lei Tang, PhD

President-Elect
Jian Liu, PhD

Immediate-Past President
Weiguo Dai, PhD

Executive Vice President
Xiaole Shen, PhD

Vice Presidents and Chapter Presidents
Zhenghua Wu, PhD, Larry Cai, MBA, Steven Yu, PhD

Executive Council (EC) Member
Charles Bao, PhD Chenciao Gao, PhD Yan G Ni*, PhD
Xingfeng Bao, PhD Yong Guo*, PhD Hong Ren, PhD
Larry Cai, MBA Mike Hu, PhD Fang Shen, PhD
Dapeng Chen, PhD Jasmine Huang Xiaole Shen, PhD
Xiaodong Chen*, PhD Lisa Huang, PhD John Tan, PhD
Han Dai, PhD Dongxuan Jia Lei Tang, PhD
Weiguo Dai, PhD Ling Kang, PhD Jianfeng Wang, PhD
Patrick Deng Jerry Li, PhD Zhenhua Wu, PhD
Wei Ding*, PhD Kejie Li, PhD Guangyao Yang*
Xin Du*, PhD Jian Liu, PhD Mingzhu Yin, PhD
Helena Feng* W. Jerry Liu*, PhD, JD Aming Zhang, PhD
Frank Gan*, PharmD Xiuling Lu, PhD Jin Zhou, PhD

*Department Directors

Board of Directors (2017-2019)
Jiwen Chen, PhD Mark Lin, PhD Mingde Xia, PhD
Jisong (Jasmine) Cui, PhD Min Li, PhD Zhi.-Xin (Rick) Xu, PhD
Weiguo Dai, PhD Yongmei Li, PhD Steven Yu, PhD
Handan He, PhD Lei Tang, PhD Hancheng Zhang, PhD
Jun-Yan Hong, PhD Huayi Tong, PhD Xiangyang (Sean) Zhang, MD
Jiangbin (John) Hu, PhD Charles Wang*, PhD Zhongda Zhang, PhD
Baoguo Huang, PhD Jianji Wang, PhD
Huo Li, PhD Yusheng Wu, PhD

*Chair of the Board of Directors
Advisory Committee Members

Bao-lu Chen, PhD  Xiaoling Li, PhD  Shifeng Wei, PhD
Harry Chen, PhD  Mark Lin, PhD  Jun Xiang, PhD
Jiwen Chen, PhD*  Shiwen Lin, PhD  Li Yan, PhD
Keting Chu, PhD  Cheng Liu, PhD  Dan Zhang, PhD
Jian Zhong Guo, PhD  Puchun Liu, PhD  Hancheng Zhang, PhD
Kewen Jin, PhD  Yongchun Shen, PhD  Yong Tony Zhang, PhD
Junning Lee, PhD  Li Shi, PhD  Qunyi Zheng, PhD
Jenny Li, PhD  DQ Wang, PhD  Jian Zhu, PhD
Jian Li, PhD  Jin Wang, PhD
Kechun Li, PhD  Jingsong Wang, PhD

*Chair of the Advisory Committee

Former SAPA Presidents

Xiucui Liu, PhD  1993-94  Yusheng Wu, PhD  2005-06
Guohua Zhang, PhD  1994-95  Charles Ying Wang, PhD  2006-07
Junyan Hong, PhD  1995-96  Hancheng Zhang, PhD  2007-08
Bill S. Wei, PhD  1996-97  Mingde Xia, PhD  2008-09
Puchun Liu, PhD  1997-98  Jisong Cui, PhD  2009-10
Junning Lee, PhD  1998-99  Jianji Wang, PhD  2010-11
Lihu Yang, PhD  1999-00  Baoguo Huang, PhD  2011-12
Rick Z.-X Xu, PhD  2000-01  Handan He, PhD  2012-13
Li Chen, PhD  2001-02  Jiwen Chen, PhD  2013-14
Jianzhong Guo, PhD  2002-03  Ning Yan, PhD  2014-15
Min Li, PhD  2003-04  Weiguo Dai, PhD  2015-16
John J. Hu, PhD  2004-05
25th SAPA Annual Conference
Organizing Committee

Conference Chair: Lei Tang, PhD
Conference Co-Chair: Jian Liu, PhD

Organizing Committee

Xiaobo Bai, PhD  Ling Kang, PhD  Charles Wang, PhD
Veronica Chen, PhD  Sam Kay  Jin Wang, PhD
Xiaodong Chen, PhD  Junfeng Li, PhD  Jack Wu, PhD
Weiguo Dai, PhD  Jerry Li, PhD  Steve Wu, PhD
Xing Dai, PhD  Pengbo Li  Aiguo Xu, PhD
Wei Ding, PhD  Hong Liu, PhD  Lin Yan, PhD
Xin Du, PhD  James Liu, PhD  Guangyao Yang
Helena Feng  Ling Liu  Shirley Ying
Frank Gan, PharmD  W. Jerry Liu, PhD, JD  Jianda Yuan, PhD
Chenchao Gao, PhD  Yan Ni, PhD  Le Zhan, PhD
Jiachang Gong, PhD  Su-Fen Pu, PhD MD  Xiaowei Zang
Hong-Ping Guan, PhD  Xiaole Shen, PhD  Aming Zhang, PhD
Yong Guo, PhD  John Sun, PhD  Tong Zhang, PhD
Yanming Jiang  Li Wan, PhD

Annual Conference Program Brochure

Xiaodong Chen, PhD  Xiaole Shen, PhD  Xiaojiao Xue, PhD
Frank Gan, PharmD  John Sun, PhD  Xiaowei Zang
Hong-Ping Guan, PhD  Lei Tang, PhD  Yiming Zhao, PhD
Jian Liu, PhD  Steve Wu, PhD
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apr 6, 2016</td>
<td>SAPA-GP Opened SAPA-GP WeChat Group with more than 1,500 followers</td>
</tr>
<tr>
<td>Jun 11, 2016</td>
<td>SAPA-NE organized 18th annual meeting with the theme &quot;Innovative Drug R&amp;D and Global Partnership: Strategies for Patient Centered and Value-based Medicine&quot;</td>
</tr>
<tr>
<td>Jul 30, 2016</td>
<td>SAPA-NE organized summer outing potluck at Hopkinton State Park</td>
</tr>
<tr>
<td>Aug 14, 2016</td>
<td>Nanjing Sanhome Pharmaceutical Co., Ltd. and SAPA-NE co-organized 2016 Career Fair in Boston</td>
</tr>
<tr>
<td>Aug 20, 2016</td>
<td>SAPA-MW, Northwestern University School of Medicine and Cheung Kong Graduate School of Business (CKGSB) successfully held Health Industry Development Summit Forum</td>
</tr>
<tr>
<td>Sep 17, 2016</td>
<td>SAPA-DC initiated the founding meeting and held first annual meeting</td>
</tr>
<tr>
<td>Sep 24, 2016</td>
<td>SAPA-GP hosted the 2016 Student Career Development Forum with huge success</td>
</tr>
<tr>
<td>Sep 27, 2016</td>
<td>KELUN Pharmaceuticals - SAPA-NE Boston Event 2016</td>
</tr>
<tr>
<td>Oct 1, 2016</td>
<td>SAPA-HQ held the 24th Annual Conference themed “Transforming Drug Development, Changing the Lives” with more than a thousand attendees</td>
</tr>
<tr>
<td>Oct 8, 2016</td>
<td>SAPA-CT successfully held the 3rd annual meeting titled “Technological progress and global innovation contribute to patient benefits”</td>
</tr>
<tr>
<td>Oct 21, 2016</td>
<td>SAPA-GP hosted Shanghai Bio-forum Delegation visit</td>
</tr>
<tr>
<td>Oct 21, 2016</td>
<td>ChPC and SAPA-NE co-organized joint open seminar titled “Current Trends in Standard Setting for China Pharmaceutical Industry”, supported by Waters Corporation</td>
</tr>
<tr>
<td>Nov 12, 2016</td>
<td>SAPA-HQ launched the first 2016-2017 Extended Executive Council Leadership Meeting</td>
</tr>
<tr>
<td>Nov 19, 2016</td>
<td>SAPA-NE organized the 19th Scientific Symposium and got a big round of applause</td>
</tr>
<tr>
<td>Nov 19, 2016</td>
<td>SAPA-DC and Beijing Pharma and Biotech Center (BPBC) hosted Beijing Biomedical Industry Crossing Development Project Promotion conference</td>
</tr>
<tr>
<td>Dec 3, 2016</td>
<td>SAPA-GP organized scientific symposium titled “Battles against Old Foes: New Frontiers in Fighting Infection Diseases” at Radnor Valley Country Club in Villanova, PA</td>
</tr>
<tr>
<td>Dec 10, 2016</td>
<td>SAPA-HQ successfully held Project Management Symposium</td>
</tr>
<tr>
<td>Jan 1, 2017</td>
<td>SAPA-GP initiated one-to-one Mentor-Mentee Program</td>
</tr>
<tr>
<td>Date</td>
<td>Event Description</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Jan 21, 2017</td>
<td>SAPA-HQ held the 2017 Chinese New Year Celebration and Appreciation Dinner Reception</td>
</tr>
<tr>
<td>Feb 4, 2017</td>
<td>SAPA-NE Chinese New Year Celebration</td>
</tr>
<tr>
<td>Feb 10, 2017</td>
<td>SAPA-GP hosted visit by Hubei Province Delegation</td>
</tr>
<tr>
<td>Mar 4, 2017</td>
<td>SAPA-HQ successfully held 2017 Career Development Workshop</td>
</tr>
<tr>
<td>Mar 18, 2017</td>
<td>The 19th SAPA-NE Career Development Symposium was successfully held</td>
</tr>
<tr>
<td>Mar 26, 2017</td>
<td>SAPA-CT initiated the 1&lt;sup&gt;st&lt;/sup&gt; Career Development Workshop titled “Jumping Out of The Circles”</td>
</tr>
<tr>
<td>Apr 1, 2017</td>
<td>2017 Immunotherapy Scientific Symposium at SAPA-DC attracted a lot of attention</td>
</tr>
<tr>
<td>Apr 7, 2017</td>
<td>SAPA-GP signed the collaboration memo with Pingyuan New District at the 2&lt;sup&gt;nd&lt;/sup&gt; China Pharmaceutical Innovation &amp; Development Summit at Hualan Industry Park in Xinxian, Henan province, China</td>
</tr>
<tr>
<td>Apr 8, 2017</td>
<td>SAPA-HQ successfully held Scientific Symposium titled “Revolution in Cancer Treatment – Immunotherapy and Beyond”</td>
</tr>
<tr>
<td>Apr 21, 2017</td>
<td>SAPA-HQ and Longwen District, Zhangzhou, Fujian province, signed a memorandum of cooperation</td>
</tr>
<tr>
<td>Apr 26, 2017</td>
<td>SAPA-GP co-sponsored the Precision Medicine and Immuno-oncology China summit 2017 in Shanghai, China</td>
</tr>
<tr>
<td>May 13, 2017</td>
<td>SAPA-CT and University of Connecticut held the 2&lt;sup&gt;nd&lt;/sup&gt; joint Scientific Symposium titled “Moving Towards the Future of Medicine”</td>
</tr>
<tr>
<td>May 21, 2017</td>
<td>SAPA-GP co-organized DIA China 9&lt;sup&gt;th&lt;/sup&gt; Annual Meeting in Beijing, China</td>
</tr>
<tr>
<td>May 27, 2017</td>
<td>SAPA-GP organized summer picnic at Peace Valley Park, PA</td>
</tr>
<tr>
<td>May 27, 2017</td>
<td>SAPA-NE organized Taizhou and Overseas High-level Talents Conference 2017 in Boston</td>
</tr>
<tr>
<td>May 31, 2017</td>
<td>SAPA-GP hosted visit by Beijing E-town Delegation</td>
</tr>
<tr>
<td>Jun 17, 2017</td>
<td>SAPA-NE successfully held the 19&lt;sup&gt;th&lt;/sup&gt; Annual Conference-“Convergence: Transformation of Life Science in Boston” in Boston</td>
</tr>
<tr>
<td>Jun 23-24, 2017</td>
<td>SAPA-GP successfully held the 15&lt;sup&gt;th&lt;/sup&gt; annual meeting with the theme “Winning for Patients: Building Global Pharmaceutical Ecosystems &amp; Delivering Breakthrough Medicines” at Sheraton Valley Forge Hotel in King of Prussia, PA</td>
</tr>
<tr>
<td>Jul 22, 2017</td>
<td>SAPA friends and families got together at the 2017 SAPA-HQ Summer Picnic</td>
</tr>
<tr>
<td>Aug 17, 2017</td>
<td>Hubei Provincial Department of Commerce Delegates Visited SAPA-GP</td>
</tr>
</tbody>
</table>
Friday, September 29, 2017

12:00 – 1:00 pm  Registration

Friday, September 29, 2017, 1:00 – 2:40 PM  Ballroom West and Center

Plenary Session 1: Life Science Landscape and Regulatory Reform in the US and China

Session Moderators: Lei Tang, PhD and Jian Liu, PhD

Keynote presentations at the plenary sessions will focus on advancing pharmaceutical and biotechnology development through global collaboration, challenges and opportunities on breakthrough and innovative therapies, capital investment, business development strategies, legal protection, and regulatory sciences. These distinguished leaders will share their experience and perspectives on global collaboration strategies and the impact on the innovative drug development and disruptive technology innovation.

1:00 – 1:10 pm  Opening Remarks
Lei Tang, PhD, SAPA President

1:10 – 1:40 pm  The New Jersey Life Sciences Industry Landscape
Debbie Hart, President and CEO, BioNJ

New Jersey is leading the way in medical innovation, expanding as a top biopharma hub. During this fireside chat with Debbie Hart, she’ll discuss:

- How New Jersey’s life sciences ecosystem has evolved
- The economic impact of the life sciences industry in New Jersey and what the future looks like
- What sets New Jersey apart from other states
- How New Jersey — known as the “Medicine Chest of the World” — contributes to the advancement of global human health
- BioNJ’s role in supporting the growth of New Jersey’s life sciences community

1:40 – 2:10 pm  ICH Reform and Future Direction: US FDA Perspective
Theresa Mullin, PhD, Director, Office of Strategic Programs, FDA/CDER and Chair of ICH management committee, FDA/CDER
Provides an overview of the organization, governance, and standards harmonization work performed by the International Council on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Describes recent reforms to ICH and discusses future direction for drug regulatory harmonization work.

2:10 – 2:40 pm  Regulatory Reform in China and Its Opportunities and Challenges for Innovative Global Drug Development
Mathias Hukkelhoven, PhD, SVP, Global Regulatory, Safety and Biometrics of BMS

Recent regulatory reform created by CFDA and its membership of ICH start to provide an environment of drug development innovation and allows for much faster development and approval times. When development plans are well executed this will allow China clinical centers to join global registration studies and in principle enable Chinese registration very close to the time of US and EU approval. However in order to truly stimulate innovation, the government also needs to act against unauthorized generics and other counterfeit drugs.

2:40 – 3:00 pm  Coffee Break

Friday, September 29, 2017, 3:00 – 5:30 PM  Ballroom West and Center

Parallel Session A: Pharma Investment Forum

Session Moderators: Jin Wang, PhD and Xiaodong Chen, PhD

Pharma Investment Forum is a premier industry gathering to connect venture capitalists, corporate venture, investment banking and angel investors with entrepreneurs. If you are an investor looking for early assets, or an entrepreneur looking for funding, visibility and growth, or a researcher gaining insights into private equity world. This session is one event you won’t want to miss.

The first half of the session will feature presentations on new investment trend both in US and China. The second half of the session will be venture panels, you will hear key issues facing investors and startups, successful cases and tips of fundraising sharing from those professionals.

3:00 – 4:30 pm  The Choice of Chinese Medicine in Changing the Global Era
Lawrence Tian, PhD, Founding Partner, Yuanming Capital

Investing in China Healthcare: Perspectives and Lessons Learned
Hongbo Lu, PhD, MBA, Partner, Lilly Asian Ventures

- What are we looking for in China and the US, in terms of investment opportunities and talents?
- Investment opportunities: me-too vs. me-better vs. me-first; internal discovery vs. in-licensing
- Talents: scientists vs. business managers; series vs. first-time entrepreneurs
- Investment sectors: drugs vs. medtech vs. healthcare services vs. digital health
Trends in Cross-border Investment and Collaboration: From the Perspective of an Investment and Advisory Firm Actively Involved in the US and China

Kimberly Nearing, Managing Director and Head of Life Sciences, Cedrus Investments

- Broad interest in exploring collaborations in China and the US
- Capital control concerns – JVs in China
- Strategic versus financial investments
- Drug development increasingly global
- Pre-clinical and innovative assets - sudden jump in ‘real’ interest
- Cross-border partnering remains strong
- Submission and approval process acumen – increasing in the spotlight for investors
- China emerging as leading producer of biotech drugs
- Strategic structuring to enable internationalization: “Biotech-innovation” start-ups in China setting up VIE (Variable Interest Entity) structures, and are looking for IPO chances in Nasdaq.
- Trust partners: needed in both regions!

The Early Investment Opportunities for Biomedical Care in China

Feng Li, Founding Partner, Frees Fund

Currently more than 80% of the national social health insurance expenditures for the purchase of imported drugs and supplies for major diseases. The gap between the current domestic medical resources and supply is apparent. It is very urgent to master the pricing power for the core drug for reducing the gap as well as this part of the national expenditure. Therefore, it is a great opportunity for early-stage investor to look through the industry of new drug research and development.

Investment of U.S. Biotech for Cross-border Synergy with China

Jing-Shan “Jennifer” Hu, PhD, Partner, Qiming U.S. Healthcare Fund

4:30 – 5:30 pm  

Panel Discussion

Additional Panelists:
Sean Cao, Managing Director, C-Bridge Capital Partners
Haipeng Cheng, Investment Director, Sangel Venture Capital
Betty Yu, CFA, Investment Banking Department, China Merchants Bank Co., Ltd., New York Branch
Wei Zhao, Senior Associate, 6 Dimensions Capital
Wendy (Wenseng) Pan, JD, PhD, Partner, Sidley Austin LLP
Sally Wang, JD, MPH, CEO & Co-founder, DocFlight
Under such a competitive environment, traditional cost-saving outsourcing has evolved into a more advanced form of outsourcing, i.e., value-creating global collaboration, to drive new revenue, shorten time-to-market, lower the entry bar for new entrepreneur, and increase innovation. In this session, we are fortunate to have several CEOs and executives from small to large CROs, and managers in charge of external collaboration from big pharma to share their strategy — how to build sustainable competitive advantages for growth with global collaboration in current pharmaceutical landscape.

3:00 – 3:15 pm  Leaping to Global Specialty Pharmaceutical Company  
Jeffrey S. Humphrey, MD, CMO and President, Kyowa Kirin Pharma Development, Inc.

As pricing pressures increase, pharmaceutical companies face increasing pressure to obtain access to new markets. Kyowa Hakko Kirin is a Japan-based company world-leading R&D type life sciences company. The company has dedicated itself to becoming a Global Specialty Pharmaceutical company in a thoughtful, stepwise fashion as outlined in successive mid-term plans. The process of Kyowa Hakko Kirin’s leap to Global Specialty Pharmaceutical Company will be presented with comment on major factors for success.

3:15 – 3:30 pm  Dawn of a New Era in Global Services  
Francis Tse, PhD, CSO, WuXi AppTec LTD

The cost of developing a NCE or new biologic continues to rise, and the journey from bench to bedside remains long and full of obstacles. On the other hand, the pharmaceutical industry has been under growing pressure from governments, third-party payers, and patients to control the price of medicines. Since the late 1900’s drug developers in the U.S. have turned to outsourcing in an effort to cut cost and save time, and CROs have quickly become an inseparable partner in the drug development landscape. With the world getting smaller and globalization creating equal opportunities and a more competitive environment, traditional cost-saving outsourcing has evolved into a new form of global collaboration. The growth of the pharmaceutical CRO sector in China during the last two decades will serve as a good example of how CROs in emerging markets must move up the value chain and drive innovation and technology in order to build a sustainable competitive advantage for continued success.

3:30 – 3:45 pm  Global Collaboration with Outsourcing — Impact on Pharma Landscape  
Joseph Duffy, PhD, Executive Director, External Discovery Chemistry, Merck

Biopharmaceutical research companies face pressure to discover increasingly innovative therapies with constrained resources. This challenge has been met over the past decade by leveraging resources external to the company to create value. Several different external models exist to meet these needs, from fee-for-service to fully externalized research projects. As a prelude to the panel discussion, this presentation will provide a brief review of the primary collaboration and outsourcing models from the “Big Pharma” perspective, and propose the appropriate conditions under which each model should be considered.

3:45 – 4:00 pm  Strategic Partnerships for Biologic R&D  
James Jianguo Yang, PhD, CEO, Abpro China

Biologic drugs on the market now have been results of partnership from R&D to commercialization. Increasing complexity of biologic drug development requires
more collaborations or partnerships in biopharma industry. This presentation will review current status of biologic drugs market and landscape and importance of strategic partnerships in biologic drug research and development, and future trends.

4:00 – 4:15 pm  
**Drug R&D in China via Innovation and Globalization**

**Weikang Tao, PhD, VP and CEO of R&D Centers, Jiangsu Hengrui Medicine Co, LTD**

China has become the 2nd largest pharmaceutical market in the world since 2014 and the Chinese biopharmaceutical industry has been undergoing profound changes over the last decade. Hengrui Medicine Co., Ltd. is an innovation-driven pharmaceutical company born in China and growing globally with a capital size of about 23.3 billion US dollars and a profit CAGR of above 25% over the last 16 years. Hengrui has achieved its growth via persistent innovation and collaborations. This presentation will highlight the current development and transformation of the pharmaceutical industry in China and introduce and discuss Hengrui’s drug R&D strategy and practice.

4:15 – 5:30 pm  
**Panel Discussion**

Additional Panelist:  
**John Yao, PhD, CEO, TC Scientific**

---

**Friday, September 29, 2017, 2:30 – 5:30 PM**  
**Tuscany**

**Job Fairs**

**Session Moderators:** Jack Wu, PhD, Xiaowei Zang, Frank Gan PharmD, Guangyao Yang

This Job Fair session is specially designed to facilitate the connections between job seekers and employers at SAPA Annual Conference. Our designated conference room provides the most efficient way for recruiting companies to communicate with prospective candidates and conduct “instant interviews”. For job seekers, this is a perfect opportunity to scope out potential employers in anonymity, and get face-to-face access to HR, Hiring Managers, and Senior Managements who are the key contacts to the next career opportunity. The job fair session brings together over thirty hiring companies and the best talents in the biotechnology and pharmaceutical industries. You can expect the connections made here have great potentials to turn into real meaningful opportunities.

---

**Friday, September 29, 2017, 6:00 – 8:00 pm**  
**Mirabelle**

**SAPA VIP Reception**

*(by invitation only)*

Sponsored by 泰州医药高新技术产业园
Saturday, September 30, 2017

7:30 – 8:45 am  Registration

8:30 am – 4:30 pm  Sponsors and Exhibition; Poster Presentation  Lobby and Foyer

3:00 – 3:15 pm  Coffee breaks

Saturday, September 30, 2017, 8:45 am – 12:00 pm  Ballroom

Plenary Session 2: Advancing Pharmaceutical and Biotechnology Development

Session Moderators: Lei Tang, PhD and Jian Liu, PhD

Keynote presentations at the plenary sessions will focus on advancing pharmaceutical and biotechnology development through global collaboration, challenges and opportunities on breakthrough and innovative therapies, capital investment, business development strategies, legal protection, and regulatory sciences. These distinguished leaders will share their experience and perspectives on global collaboration strategies and the impact on the innovative drug development and disruptive technology innovation.

8:45 – 9:10 am  Keynote Remarks

Lei Tang, PhD, SAPA President
Jijun Xing, PhD, Science and Technology Counselor in Chinese Consulate-General in New York

9:10 – 9:40 am  Engineering Bispecific Antibodies to Block HIV Transmission

David Ho, PhD, Scientific Director, CEO, and Professor of Aaron Diamond AIDS Research Center

An efficacious vaccine against HIV remains a challenge due to the inherent obstacles posed by the structure of the viral envelope glycolprotein. Antiretroviral drugs could protect against HIV transmission when taken as pre-exposure prophylaxis; however, the overall efficacy is modest due to inadequate adherence to the drug-taking regime. The use of potent HIV neutralizing monoclonal antibodies as passive immunization has gained traction in recent years. We have engineered a library of bispecific antibodies in search of ones that could potently neutralize a large library of diverse strains of HIV. We have identified a bispecific antibody as our clinical lead. This candidate antibody for HIV prevention is now in GMP manufacturing and a first in-man clinical trial is expected in the first quarter of 2018. The efforts behind the development of this bispecific antibody will be described.

9:40 – 10:10 am  Breakthrough Innovation for the Treatment of Autoimmune Diseases

Christian Antoni, MD, PhD, VP, Head of Immunology Development, Sanofi

The rapidly increasing understanding of the inner workings of the immune system combined with the advent of biotherapies has ignited a strong innovation
momentum in the treatment of autoimmune diseases. Sanofi have made this therapeutics area a key pillar of their roadmap to 2020 as exemplified by the approval this year of two innovative drugs, Dupixent® for the treatment of moderate to severe atopic dermatitis and Kevzara® for the treatment of rheumatoid arthritis. Sanofi’s current ambition is to ensure people around the world can access these innovative treatments and a strong commitment is being made to obtain their approval in China. Beyond this Sanofi is committed to address remaining unmet needs for patients suffering from autoimmune diseases around the world and to discover innovative therapies.

10:10 – 10:15 am Announcing SAPA President and EC Election Results
SAPA President Office

10:15 – 10:30 am Coffee Break

10:30 – 11:00 am A Journey to Build $5b Company in 6 Years
Chris Chen, CEO, WuXi Biologics

WuXi Biologics (2269.HK) is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. The company was established in June 2011 as a department of WuXi PharmaTech. Our business model is built on a “follow-the-molecule” strategy: our customers’ demand for our services increases as their biologics advance through discovery, development and manufacturing. IP is our shared lifeline. Our purpose in business is to enable innovation for our global partners, who keep us at the top of their confidence.

After six years’ rapid development, WuXi Biologics was listed on the Hong Kong Stock Exchange as a separate company on June 13, 2017:

We provide our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. We have 130+ global partners, including 12 of the top 20 multinational pharmaceutical companies in the world. We have passed 60+ GMP audits and completed an FDA PLI audit in 2017 Q3.

We provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients.

11:00 – 11:30 am Tri-I TDI – A Novel Academic Business Model
Michael Foley, PhD, Director of Tri-I TDI and Sanders Innovation and Education Initiative

TDI is a non-profit 501(c)(3) organization founded in 2013 as a novel partnership between three world-class research institutions: Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University (RU), and Weill Cornell Medicine (WCM). TDI helps biomedical researchers across the three institutions to advance their groundbreaking basic research discoveries along the path from laboratory to the clinic. A Tri-Institutional (Tri-I) researcher who has identified a promising new drug target is invited to submit proposals for consideration by an independent SAB. Upon review, the SAB recommends meritorious projects for the TDI Small Molecule or Antibody Initiative. Once accepted, TDI-partnered discovery projects receive a comprehensive menu of services, culminating in delivery of a lead small molecule or antibody appropriate for evaluation in in vivo proof-of-concept studies. After three years of operation, TDI now has a portfolio
of 51 small molecule and antibody drug discovery projects, each of which has the potential to lead to a new treatment for an unmet medical need.

11:30 am – Noon  **When Science Is a Business**
Yiwu He, PhD, MBA, SVP of International Business, BGI

Modern life sciences many times present exciting business opportunities when cutting edge discoveries immediately lead to products with huge financial potentials. However, not every intelligent scientist is also a wise businessman. This presentation focuses on discussions why first class research is critical to be combined with right business strategies for biotech companies to compete successfully, and to stay ahead of the game that frequently the winner takes it all.

Noon – 1:00 pm  **Lunch**  Mirabelle

Saturday, September 30, 2017, 1:00 pm – 3:00 pm  **Ballroom East**

**Parallel Session C: Business Development Forum**

**Session Moderators:** Tong Zhang, PhD, Aming Zhang, PhD, and Frank Gan, PharmD

**Co-Organizer:**

BioKatalyst

**Session Title Sponsor:** Humanwell

The importance of the business development and licensing (BD&L) function in the global biotech and biopharmaceutical industries has grown significantly over the past 20 years, as companies have sought to supplement their internal R&D with innovative products and technologies sourced through external licensing, joint ventures, acquisition of intellectual property rights, collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. These have required companies to employ BD&L executives to search, evaluate, negotiate and manage deals and alliances ranging from academic research institutes, to small biotechnology companies, and to the largest of the Big Pharma companies. The BD&L session at SAPA Annual Conference offers a unique opportunity to learn from industry experts on their valuable experience and latest industry trends. Don’t miss your chance to engage in discussions with speakers, hone your professional knowledge, and network with industry peers.

1:00 – 3:00 pm  **Transformation of BeiGene via Business Development and Partnership**

Ji Li, PhD, EVP, Global Head of Business Development, BeiGene Ltd.

BeiGene was founded in 2011 as an oncology focused startup based in Beijing, China. Today, BeiGene is listed on the NASDAQ market as a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 600 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. I will discuss the essential role business development and partnership played in transforming BeiGene from a discovery oncology startup to a fully integrated biopharmaceutical company with discovery research, clinical development, small molecule and biologic manufacturing and commercialization capabilities in such short period of time.
Fosun Pharma: Combining China’s Momentum with Global Resources

Lily Zou, CEO, Fosun Pharma USA

Fosun Pharma, a top Chinese Pharmaceutical company, has seen rapid and sustained expansion driven by both organic growth and external collaborations and acquisitions. With heavy investment in R&D, improvement in manufacturing facilities, and expansion into global markets, Fosun Pharma aims to become a global leader in the healthcare industry.

Additional Panelists:

- Tong Zhang, PhD, SVP, Head of Corporate BD, WuXi AppTec
- Michael Keyoung, MD, PhD, Managing Director and Head of North America, C-Bridge Capital
- Zhongda Zhang, PhD, VP, Business Development, Pharmaron
- Hanzhong Li, CFO, Ascentage

Saturday, September 30, 2017, 1:00 pm – 4:30 pm  Ballroom Center

Parallel Session D: Regulatory: Breakthrough Therapy and Its Applications

Session Moderators: Xin Du, PhD, Li Wan, PhD and Veronica Chen, PhD

Since its implementation in 2012, breakthrough therapy (BT) designation has been playing an significant role in drug development. Breakthrough therapy designation expedites the development and review of drugs for serious or life-threatening conditions. Many companies applied for such designation. So far, more than 100 BT designations have been granted, most of them in the immuno-oncology therapeutic and other unmet and serious disease areas.

This regulatory section will discuss the benefits of BT designation, its accordance criteria and application procedure. Case studies will provide more sight on how to quality for the BT designation, how to apply for it and how it impacts the overall drug development and approvals.

1:00 – 4:30 pm  Overview of FDA Expedited Approval Programs

Robert Ashworth, PhD, SVP, Regulatory, Advaxis

To expedite the development, review and approval of drugs for serious or life-threatening conditions, the FDA established four programs. These programs provide significant benefits to the companies in their drug development and could the high-quality drug products to the patients in fast-paced pathways.

This presentation will discuss the FDA expedited approval programs, including the breakthrough therapy designation which include most of the other program features, more intensive FDA guidance on an efficient drug development program, an organizational commitment involving senior managers, and eligibility for rolling review and priority review.

Overview of Breakthrough New Drugs in China

Dan Zhang, MD, MPH, CEO, Fountain Medical Development Ltd.

Although there is no FDA-style “breakthrough therapy designation” regulatory pathway in China for the new drugs, China’s CFDA has policies in place to push the new drugs that could bring significant benefits to patients in a fast-track pathway,
which encourage the development of such new drugs. This presentation will discuss the status of the new drug development and the policies in China.

**Legal Considerations for the FDA Breakthrough Therapy Designation**

**Shahnam Sharareh, PharmD, RAC**, Partner Fox Rothschild LLP

This presentation will discuss the legal consideration for the FDA Breakthrough therapy designation.

**Breakthrough Therapy Designation Application for dupilumab and evinacumab**

**Elisa Babilonia, PhD**, Associate Director, Regulatory, Regeneron

To expedite the development, review and approval of drugs for serious or life-threatening conditions, the FDA established four programs, one of which is Breakthrough Therapy Designation. These programs provide significant benefits to companies during drug development and expedite access of highly needed medicines to patients with serious conditions. This presentation will discuss the FDA breakthrough therapy designation benefits, using our experience with Dupilumab as a case study.

---

**Saturday, September 30, 2017, 1:00 pm – 4:30 pm**  
**Ballroom West**

**Parallel Session E: Scientific Session: Immuno-Oncology**

**Session Moderators:** Junfang Li, PhD, Su-Fen Pu, MD, PhD, and Jerry J Li, PhD

Immuno-oncology has revolutionized cancer treatment over the past decade and continues to yield new and exciting results. More and more new immunotherapies come into the clinics, from monoclonal antibody targeting the next generation of checkpoint inhibitors to oncolytic viral therapy, CAR-T cell therapy, and new cancer vaccines. The therapeutic approaches ranging from activating patients’ own immune system to attack cancer cells to neutralizing mechanism to regulate patient’s immune system, are increasingly implemented with much improved efficacy and unique safety profile which result in better quality of life for patients.

In this exciting scientific session, the leading experts in the immune-oncology field will present the latest progress in cancer immunotherapy and novel clinical study designs, as well as recent innovations in cutting edge technology in pharmaceutical industry.

**1:00 – 4:30 pm**

**Next Generation Cancer Immunotherapy**

**Guanghui Hu, PhD**, CEO, Ademera

In this presentation, the speaker will review the current status of cancer immunotherapy and highlight some emerging innovations, in particular the “regulatable” CAR-T technology (by inserting an “on-off switch”) to enable the development of next generation CAR-T therapies.

**A Case Study in Development of Personalized Immunotherapy**

**Cong Chen, PhD**, Director of Early Oncology Biostatistics, Merck.

Pembrolizumab’s success and Nivolumab’s setback in 1L NSCLC last year had a profound impact on the landscape of immune-oncology development. In this presentation, I will shed light on the key decision-making processes that led to the constrasting outcomes.
IG Repertoire Analysis and Functional Antibody Discovery
Grace Qiao, PhD, Sr. Bioinformatics Analyst, GeneWiz

The advancement of high throughput sequencing technology and data analysis has made it time-efficient and cost-effective to analyze immunoglobulin (Ig) repertoires. The comparison of the Ig repertoires between healthy and diseased states has various applications in life science and health care including antibody discovery. Here we will present studies on utilizing peripheral Ig repertoire analysis to facilitate antibody discovery in cases of vaccination or infection. Briefly, PBMCs from patients or volunteers were obtained at different stages for Ig repertoire characterization. Based on the analysis, a limited number of heavy and light chain sequences were selected and synthesized for antibody expression and screening. Positive clones were obtained in both cases.

SMAB: A Versatile Platform for Next-Generation Therapeutic Antibodies
Chuan-Chu Chou, PhD, CEO, Qragen Biotech

Camelid antibodies have been known to be highly stable and confer high affinity binding to antigens. Their antigen-binding domain, VHH, are small, usually 12-13 kDa, are thought to have advantages over traditional antibodies in accessing epitopes that are difficult to target by traditional antibodies. Multiple units of such single-domain antibodies (sdAb) can be connected as “homomultimers” to increase efficiency of target engagement, or as “heteromultimers” to target multiple molecules or multiple epitopes of the same target. Based on such properties of camelid antibodies, we developed a platform of therapeutic antibodies which work likes a homing missile with multiple warheads. In a typical arrangement, one or more single-domain antibodies are fused via linkers with a monoclonal antibody to become bi- or multispecific antibodies with extended serum half-life. Examples will be presented to demonstrate the feasibility and in vivo validation of the concept, which can be applied to generating a variety of powerful weapons to eliminate disease causing cells including cancer, soluble or membrane-bound molecules, or pathogens as a first-line treatment.

Next Generation Biomarker for Personalized Cancer Immunotherapy
Jianda Yuan, MD, PhD, Director of Translational Oncology at Early Oncology Development, Merck

Immune checkpoint blockade therapies are revolutionizing the standard cancer treatment. Despite the current success of these therapies, not all patients respond to immunotherapy and even those that do often experience toxicities. Combination approaches are the keys to improving clinical response. From preclinical immune-oncology mouse models to patients enrolled on clinical trials, novel high throughput technologies enable us to understand the mechanisms underlying the complex interactions between the immune system and cancer, identify predictive biomarkers for the patients who will most likely benefit from current immunotherapies, avoid immune-related adverse events and guide the future combination cancer immunotherapy.
Parallel Session F: 2017 SAPA Startup-Venture Summit – Where Innovation Meets Capital

Session Moderators: Xiaodong Chen, PhD, Lei Tang, PhD, Jin Wang, PhD, Le Zhan, PhD

Are you passionate about starting your own business or building your own company? Would you like to bring your unique science/technology into real-life applications? What is the most efficient way to “pitch” your business plans to investor? How to choose a startup company to work with, or to invest? What is the risk and benefit? If you are curious about any of these questions, don’t miss this brand new SAPA Startup-Venture summit. There will be industry leaders in investment (VC/PE) and Business Development to join us as panelists and advisors. Ten early to middle stage biotech/life science startup companies will be selected to share their venture “pitch”.

This summit is designated to bridge startups and investments, to exchange innovative ideas and business plans, to analyze the pros and cons of a startup, to help you judge if you are ready to be your own boss, to inspire more forthcoming creative thoughts and executions. Come and join this exciting half day event and be prepared, you can connect with investors, startups and potential partners through this high level networking opportunity.

1:00 – 5:30 pm

Roadshow Advisors:
Lawrence Tian, PhD, Founding Partner, Yuanming Capital
Fanzhi Huang, MBA, Co-Founder, Partner, Share Capital Corp
Jin Wang, PhD, CEO, Manhattan Capital
Haipeng Cheng, Investment Director, Sangel Venture Capital
Wei Zhao, Senior Associate, 6 Dimensions Capital
David Wang, MBA, Partner, The Maverick Capital
Kimberly Nearing, Managing Director and Head of Life Sciences, Cedrus Investments
Hongbo Lu, PhD, MBA, Partner, Lilly Asian Ventures
Jing-Shan “Jennifer” Hu, PhD, Partner, Qiming U.S. Healthcare Fund
Baixin Teng, Hangzhou Wise Wealth-Sharing Investment Management Company
Mark Tang, PhD, MPH, Managing Director, Good Health Capital
Yubo Bao, Senior Partner, MSQ Ventures
Wendy (Wenseng) Pan, PhD, JD, Partner, Sidley Austin LLP

Parallel Session G: Career Development Session: The “Yin” and “Yang” of Career Development

Session Moderators: John Sun, PhD, Ling Kang, PhD and Jiachang Gong, PhD

In Chinese philosophy, Yin and Yang describe how seemingly opposite or contrary forces may actually be complementary, interconnected, and interdependent in the natural world, and how they may give rise to each other as they interrelate to one another. This concept can be readily applied to our journey on career planning, development, and advancement. Each of us have our own strength and weakness, also we need to consciously and effectively engage the external world. There are many examples of Yin and Yang balance or imbalance, and this session will dive deep and unveil the mask of career mysteries, ranging
from different dimensions. Come to be intrigued and stimulated. Either way, this session will make you think differently about yourself on how to live a more productive and fulfilling life.

1:00 – 5:00 pm

**Sara Bonstein, MBA**, EVP and CFO, Advasix
**Kevin Huang, PhD**, Chief of Staff, WuXi Biologics
**Pattie Drake**, VP Market Operations & Strategy Realization, Merck
**Don Warkentin**, Director of Training, Dale Carnegie
**Lauren Supraner**, President, CAL Learning
**Weiyong Sun, MD, PhD, MBA**, Sr Dir, External Scientific Affairs, Global Business Development and Licensing, Daiichi Sankyo Group
**Zhihong Ge, PhD**, AVP, Head of Global Development Quality, Merck
**Zili Li, MD, MPH**, Asso. Dir for Global Affairs, Office of Generic Drugs, FDA

This session will also feature an interactive workshop “The Secrets of Career Success: Communication and Leadership Skills” from Dale Carnegie. One of the secrets of a successful career is strong communication and leadership skills. Collaborating with others is a critical competency for business professionals today. In many organizations, we must achieve results through others even when we do not have direct authority, thus relying on our ability to influence. In this workshop, we will explore the impact we can have on others when we consciously apply Dale Carnegie’s principles for becoming even more effective leaders and communicators. These powerful principles will form the basis for an interactive workshop where we’ll explore the relationships around us and what we can do to maximize those relationships for career success.

**Saturday, September 30, 2017, 3:30 pm – 5:30 pm**
**Hillsborough (2nd floor)**

**Parallel Session H: The 2nd SAPA Annual Chinese CEO Forum – Stories Beyond the News**

**Session Moderators**: Charles Wang, PhD, Lei Tang, PhD and Jian Liu, PhD

The SAPA Chinese CEO Forum is a unique platform for education, discussion and debate around current and future challenges and opportunities in the pharmaceutical industry.

Featured presentations will track the industry trends and provide projections and insights into future growth and development. It will also provide participants with strategic information needed as portfolios continue to advance and evolve. Topics will include healthcare policy and regulatory reform, economic models impacting the industry, current challenges in recruitment and talent development, successful recent M&A between U.S. and Chinese companies, and opportunities in unique and beneficial partnership structures. There will be a round-table discussion following the presentations for in-depth interaction with participants. You will get to hear true stories, opinions, and solutions from successful CEOs from both US and China; and have your questions answered by the industry leaders.

3:30 – 5:30 pm

**Jinsong Cui, PhD**, President and CEO at InnoCare Pharma
**Jiangbin John Hu, PhD**, Vice President, Huahai Pharmaceutical
**Dahai Guo**, CEO at PuraCap
**Jim Huang, PhD**, Founder & CEO at Ascendia Pharmaceuticals
**Weikang Tao, PhD**, CEO Jiangsu HengRui Medicine CO., Ltd, R&D Centers
**Jianguo Yang, PhD**, President and CEO at Abpro China
**Sean Xinghua Hu, PhD, MBA**, SVP and Head of Consulting, Americas Pharmaceuticals and Diagnostics
**James S Yan, PhD, MD, DABT**, Executive Vice President Head of Early Development and Drug Safety, ZAI Lab
**Dan Zhang, PhD, MD**, CEO, Fountain Medical Development Ltd
Parallel Session I: **Beyond R&D: Commercialization and Marketing in Pharmaceutical Industry**

**Session Moderators:** Shirley Ying, Sam Kay, CFA, and Xiaole Shen, PhD

Beyond R&D is a session that focus on the final stage of product development – Commercialization. After several years in development, your work is finally ready but now what? What do we need to do to bring it to the market and patients? What are the challenges and opportunities in this ever-changing industry? Who’re involved? How to leverage real-world data and predictive analytics available? How to have a seamless commercialization plan? It will take days to cover everything.

This session will however offer a glimpse of the world beyond R&D through the eyes of seasoned pharmaceutical executives in the sales, marketing, operations, access, and finance functions, as well as networking opportunity with industry experts from a very diverse backgrounds.

**1:00 – 4:00 pm**

**Pattie Drake, VP, Market Operations & Strategy Realization, Merck**

The marketplace is evolving quickly and the pharma business model must evolve as well to reflect the changes. As increasing health care pressure challenges the pharma business, we need to transform our payment models, use data and analytics more effectively and increase our focus on consumers as they begin to bear more cost. The trend of transforming from volume to value is at a variable pace across the US and consolidation of providers is happening rapidly. There are great commercialization implications as a result of these trends.

Sales, Marketing and Access organizations need to transform in order to reflect these changes in how we commercialize our medicines. The methodologies and analytics we use in our sales force deployment and talent acquisition need to change as a result. This discussion will be led by Pattie Drake, Vice President US Operations and Strategy Realization at Merck.

**Shirley Ying, VP, Head of Enterprise Data Strategy and Analytics,**
**Komodo Health**

**Sam Kay, CFA, Asso. Dir, US Strategy Partnering & Operations,**
**Novartis**

Parallel Session J: **IP Protection, Licensing, Enforcement, or Challenge as Business Strategies in Pharmaceutical and Biotech Industries**

**Session Moderators:** Wansheng Jerry Liu, PhD, JD and Hong Liu, PhD, JD

Intellectual Property is the lifeblood of pharmaceutical/biotech industries, often the only asset of a start-up or emerging company, and sometimes the very reason that a pharmaceutical/biotech company exists. Therefore, IP protection is crucial to a company’s business success, IP licensing is often the core of business transactions, and IP right enforcement and/or challenge has become an integral part of business strategies. As a result, high-profile patent litigations or IP right declarations are taking place in higher frequencies, often before any commercial value of the technology at issue has been proven or realized, and 8- or 9-digit patent licensing fees in hot therapeutic areas or multi-billion dollar verdicts in high-profile patent lawsuits have become norms rather than exceptions.
This session will feature presentations and panel discussions by experienced in-house patent attorneys or IP managers as well as litigators and legal counsel from law firms on new development of pharmaceutical/biotech patent laws and trending legal strategies in IP protection, enforcement, licensing, valuation, and commercialization. Attendees will not only be able to gain valuable insight of various recent headline-grabbing patent lawsuits, but also be provided with opportunities to directly interact with the speakers to gain first-hand knowledge or information on any aspects of pharmaceutical patent laws.

1:00 – 1:30 pm  
**2017 Patent Trends**  
Gerard P. Norton, PhD, JD, Partner, Fox Rothschild LLP

This presentation will discuss: (1) exceptions to patent eligibility, e.g., law of nature, natural phenomena, and abstract idea (2018 Congress to address amending statute to include language “subject matter existing in nature independently of or prior to and human activity”); and recent US Supreme Court Cases concerning: (2) restriction on venue of patent infringement cases to State of incorporation of defendant and where defendant has committed acts of infringement and has a regular and established place of business (TC Heartland LLC v. Kraft Foods Group Brands LLC); (3) patent lawsuit issues related to statute of limitation: no laches in patent infringement cases and 6-year limit on damages (SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC); and (4) patent exhaustion doctrine – once patent owner sells a patented product, all patent rights are extinguished (Impression Products, Inc. v. Lexmark International, Inc.). In addition, the presentation will discuss (5) inter partes review on whether it will continue to be the preferred procedure for challenging patentability as well as the estoppel issues in the inter partes review.

1:30 – 2:00 pm  
**Case Study: Obtaining and Enforcing Therapeutic Antibody Patent Claims**  
Jamie Hu, PhD, JD, IP Counsel, Legal & Corporate Affairs, Novo Nordisk

In 2016, therapeutic monoclonal antibody drugs have combined sales exceeding $81 billion. This number is expected to continue to grow given a large number of antibody drugs are currently in the pipeline. Meanwhile, therapeutic antibody patents have become increasingly important. Case study of recent high-profile Amgen v. Sanofi/Regeneron case involving ongoing anti-PCSK9 antibody patent dispute will shed some light on obtaining and enforcing therapeutic antibody patent claims.

2:00 – 2:30 pm  
Jing Sun, PhD, Asia Pac IP Lead, Bristol-Myers Squibb  
Hong Liu, PhD, JD, Senior Corporate Counsel, Bristol-Myers Squibb

The presentation is intended to share challenges and insights on patent prosecution and IP strategies in Life Sciences sector, with a focus on the differences between the U.S. and Chinese systems. It will also compare respective standards for patentability, with a focus on inventive step (non-obviousness) and enablement, including data disclosure in regards to the procurement of patents and the breadth of claims that may be granted.

2:30 – 3:00 pm  
**Trend of Cross-border IP Transaction in Drug Development**  
Lihua Zheng, PhD, JD, Partner, Liu, Zheng, Chen & Hoffman LLP

The presentation will summarize the key legal issues and how those issues affect business outcomes in cross-border IP transaction either in connection with an investment or as a standalone transaction. More specifically, the presentation will focus on IP due diligence in business transactions, major components of cross-
border patent license or joint venture agreements, and the trend in structuring an IP transaction in drug development.

3:00 – 3:15 pm  **Coffee Break**

3:15 – 3:45 pm  **IP Protection and Licensing as Business Strategies in Pharmaceutical and Biotech Industries – Academic Perspective**
**Tatiana Litvin-Vechnyak, PhD, ED, Licensing & IP, Rutgers University**

*Rutgers Office of Research Commercialization is dedicated to transforming research at Rutgers into products, services and partnerships for the public good, generating value for the University and enhancing economic development in the State of New Jersey. We actively engage with faculty and university partners to manage technology lifecycle for Rutgers inventions from conception through patenting, marketing and licensing to either established industry partners or startup companies based on university technology.*

3:45 – 4:15 pm  **Valuation Issues for Pharma/Biotech IP**
**Jonathan Jiong Tang, CFA, MBA, Sr Mgr, Empire Valuation Consultants**

*Intellectual property is the lifeblood of modern day business. This is especially true for the biomedical sector where the probability of success is often low and the cost of research and development can run into the hundreds of millions of dollars for one single IP. The proper understanding of the value of its IP is vital to a company’s strategy and success. This presentation will introduce various methodologies for the valuation of IP, with a special focus on the assumptions and techniques unique to the biomedical field. The audience will gain a better understanding of different valuation approaches and deeper insights into their applications through a detailed case study.*

4:15 – 5:00 pm  **Panel Discussion**
**Additional Panelists:**
**Jianming Jimmy Hao, PhD, JD, MBA, Partner, Fox Rothschild LLP**
**Jin Zhu, PhD, JD, Attorney, Fox Rothschild LLP**

---

**SAPA Reception and Annual Gala Dinner**

*Tickets are required attending the SAPA Reception and Annual Gala Dinner.*

5:30 – 6:30 pm  **Reception**
*Mirabelle*

**Presentations:**
**Wilson Lee**, Director, Sino-Singapore (Chengdu) Innovation Park (SSCIP)
**Jason Ning**, Managing Director, AIG Financial network in NJ

6:30 – 9:00 pm  **SAPA Annual Gala Dinner**
*Ballroom*

**Masters of Ceremony: Helena Feng and David Cragin, PhD**

6:30 – 6:45 pm  **SAPA Year in Review**
**Lei Tang, PhD, SAPA President**

6:45 – 7:00 pm  **Awards Ceremony**
**Lei Tang, PhD, SAPA President,**
**Jian Liu, PhD, SAPA President-Elect**

7:00 – 9:00 pm  **Dinner and Networking**
Christian Antoni, MD, PhD
VP, Head of Immunology Development, Sanofi

Christian Antoni, Vice President, is the Development head of the Immunology & Inflammation (I&I) Therapeutic Area at Sanofi. The Therapeutic Area is responsible for the development of compounds from early development through registration in autoimmune diseases and, in alignment with research and commercial, the strategic positioning of Sanofi in this field.

As such, Christian plays a key role in partnering with research and commercial to define the I&I portfolio through developing an internal pipeline and in qualifying new external opportunities. As franchise head he is building a high performing organization with the goal to successfully develop breakthrough products for high unmet needs in time and cost effectively.

Christian Antoni joined the pharmaceutical industry in 2004 as Group Director, Clinical Immunology for Schering Plough where he was involved in the clinical development, registration and medical affairs activities for biologics indicated in auto-immune diseases such as Psoriatic Arthritis, Rheumatoid Arthritis, Psoriasis, Ulcerative Colitis and Crohn’s disease.

In 2008 he moved to Novartis where as VP and Global Program Head he was responsible for bridging the link between the translational organization in the Novartis Institute of Biological Research and the Development Franchise for the autoimmune portfolio. In 2012, he became the Global Program Head for Secukinumab, the first anti-IL17 monoclonal antibody, where he created a development program in multiple indications resulting in a successful registration ahead of the competition.

Christian is a qualified MD/PhD and completed his medical training at Friedrich Alexander University, Germany and John Hopkins Hospital. He took his residency training in Internal Medicine and Rheumatology.

Robert Ashworth, PhD
SVP, Regulatory, Advaxis

Dr. Robert Ashworth has over 30 years of pharmaceutical industry experience spanning chemistry research and regulatory affairs. During the course of his career, he has made significant contributions to the FDA approvals of 12 new drugs. His drug development and regulatory experience includes small molecules, therapeutic proteins and antibodies. He joined Advaxis from NPS Pharmaceuticals Inc., where he served as Vice President, Global Regulatory Affairs and spearheaded the global approval of drugs for rare diseases. Prior to that, he had similar roles at Otsuka Pharmaceutical Development and Commercialization, Inc. and Biovail Corporation. Earlier in his career, he held positions of increasing responsibility at Forest Laboratories Inc., BASF Pharma (Knoll) and Ciba-Geigy Corporation.

Dr. Ashworth holds a doctorate in organic chemistry from the Massachusetts Institute of Technology and a Bachelor of Science in chemistry from St. John’s University.

Elisa Babilonia, PhD
Associate Director, Regulatory Affairs
Regeneron Pharmaceuticals, Inc.

Dr. Babilonia has over 10 years of experience in Regulatory Affairs in the Biopharmaceutical Industry. She is the regulatory lead for Dupixent™, a biologic recently approved for the treatment of atopic dermatitis that is also in clinical development for other inflammatory diseases such as asthma, nasal polyps and eosinophilic esophagitis. She holds a Ph.D. in pharmacology from New York Medical College and conducted postdoctoral research in physiology at Harvard.

Sara Bonstein, MBA
Executive Vice President and Chief Financial Officer, Advaxis

Ms. Bonstein joined Advaxis in March 2014 as the Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems and Johnson & Johnson. While at Eli Lilly & Company, Ms. Bonstein was a
Six Sigma Champion and Black Belt, leading multiple projects relating to clinical research, project management, finance, manufacturing and commercial sales. Prior to her Six Sigma role, Ms. Bonstein held positions of increasing responsibility at ImClone (which was acquired by Eli Lilly in 2008) including Director of Finance where she led all budget and forecast activities for preclinical, clinical and manufacturing research and development, spanning over 10 monoclonal antibody cancer therapeutics, including ERBITUX® (cetuximab), a cancer treatment with over $1.5 billion in annual sales.

Prior to joining ImClone, Ms. Bonstein was a financial analyst at Johnson & Johnson in both the Ortho McNeil Pharmaceuticals and Ortho Biotech Divisions of the company where she managed gross-to-net analysis and calculation for approximately $1.1 billion of pharmaceutical product sales. Ms. Bonstein is a 2004 graduate of Johnson & Johnson's Financial Leadership Development Program. She holds a Bachelor of Science in Finance from The College of New Jersey and a Master of Business Administration from Rider University.

Sean Wuxiong Cao, PhD
MBA, Managing Director, C-Bridge Capital

Dr. Sean Cao is the Managing Director of C-Bridge Capital, a healthcare VC fund based in China with $700M AUM. Prior to that, Dr. Cao was VP of Global Business Development at Simcere Pharmaceutical Group, responsible for the global BD strategy for Simcere, including licensing, acquisition, partnering and investment activities. Dr. Cao was also the President and Board Director at Simcere of America, a wholly-owned subsidiary of Simcere. Prior to that, Dr. Cao was the Senior Director of Alternative Partnership, Evaluation & Expertise at Sanofi, where he led the externalization effort in Global R&D. In addition, Dr. Cao was also responsible for managing the evaluation of acquisition/innovation opportunities, directly responsible for the due diligence of multiple investment decisions worth more than $4B. Before Sanofi, Sean was an associate at New Leaf Venture Partners, a leading healthcare VC firm based in New York. Sean worked in the pharmaceutical and diagnostic industries for over eight years before joining New Leaf, first at Aventis, then at Johnson & Johnson. Sean is a member of BayHelix, a premier organization of Chinese life sciences business leaders. Sean holds a Ph.D. in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a B.Sc. in Microbiology from Nankai University.

Cong Chen, PhD
Direct or of Early Oncology Biostatistics, Merck

Dr. Cong Chen is Director of Early Oncology Biostatistics at Merck & Co., Inc. He joined Merck in 1999 shortly before he graduated from Iowa State University with a Ph.D. in statistics. As head of the group, he oversees the statistical support for the clinical development of early stage oncology programs at Merck. Prior to taking the role in March 2016, he led the statistical support for the NDA filing and multiple sNDA filings of pembrolizumab (KEYTRUDA), a paradigm changing anti-PD-1 immunotherapy. He played a pivotal role in accelerating the development program, and won the Division Award, the highest individual accomplishment award at Merck Research Labs, multiple times for his distinguished contribution. He is a Fellow of American Statistical Association, an Associate Editor of Statistics in Biopharmaceutical Research, a member of Cancer Clinical Research Editorial Board and a co-leader of the DIA Adaptive Design Small Population Work Stream. He has published over 70 papers and 8 book chapters on design and analysis of clinical trials, and was twice invited to give an oral presentation at the AACR Annual Meeting on oncology drug development strategies in recent years.

Chris Chen, PhD
CEO, WuXi Biologics

Dr. Chris Chen is currently Chief Executive Officer of WuXi Biologics (2269.HK), a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics with 2300 employees and 3 R&D sites, leading biologics service business in China. At WuXi Biologics, he has built a world-class open-access integrated mAb discovery, development and manufacturing platform to service needs from global clients. Under his leadership, WuXi Biologics became the first company in China to build capabilities to develop fully human mAbs, the first company to complete IND-enabling CMC package for mAbs for global registration, first company to successfully build a cGMP biologics manufacturing facility, the first company to develop novel Antibody Drug Conjugate for global client in China and the first company to supply biologics drug substance and sterile drug product to US clinical trials. Overall he has participated in developing 11 mAb programs in US and another 50+ in China.

Haipeng Cheng, PhD
Investment Director, Sangel Capital Corp

Dr. Chris Chen is currently Investment Director at Sangel Capital Corp., a China-U.S. cross border life science venture capital firm. Dr. Cheng's life science experience spanned over 15 years as venture capitalist, entrepreneur and scientist. He also serves as executive committee member at SAPA-MW. At Sangel Capital he supports new investment evaluation, deal sourcing and provides technical and business support for portfolio companies. He focuses on investments in biomedicine, molecular diagnostics, medical devices, healthcare IT and bio-tech in U.S. Prior to Sangel Capital, he
worked at the University of Chicago and Northwestern University. Previously, he worked at United Gene Group. He has co-authored more than 30 publications in life science field. He earned his Ph.D. in genetics from State Key Laboratory of Genetic Engineering at Fudan University, Shanghai, China.

Chuan-Chu Chou, PhD  
CEO, Qragen Biotech  
Chuan-Chu Chou currently served as the CEO of Qragen, a biotech company specialized in developing multi-specific antibodies for disease treatment. Prior to Qragen, Chuan-Chu worked for Amgen, Schering-Plough, and Merck, and was a leader of drug discovery for both large and small molecules. He was the original inventor of Cinquaer (reslizumab) which was approved by the FDA as a treatment for severe asthma. He made key contributions in the discovery of Vircirviroc, a CCR5 antagonist targeting HIV infection. Most recently he co-invented a chimeric antigen receptor T-cell therapy (CAR-T) which yielded phenomenal outcomes in treating patients with multiple myeloma. Chuan-Chu received his college and Master degrees from National Taiwan University and his Ph.D. from the University of California at Los Angeles.

Jasmine (Jisong) Cui, PhD  
President & CEO, InnoCare Pharma Ltd.  
Dr. Jasmine (Jisong) Cui is the co-founder, President & CEO of InnoCare Pharma Ltd. InnoCare is a biopharmaceutical company rooted in China with the global vision to discover and develop novel treatment for cancer and autoimmune diseases. Prior to founding InnoCare, Dr. Cui was the General Manager of BioDuro (2011-2015). Her area of responsibility included BioDuro’s overall scientific and operational management, as well as business & resource management. Before BioDuro, Dr. Cui worked at Merck Research Laboratories for 14 years serving as Director of Cardiovascular Diseases where she provided project leadership for developing several drug candidates. She also served as the Chair of Early Development Team for development of drug candidate from preclinical to clinical phase 2a for POC in humans. Additionally she headed the hypertension exploratory biomarker for identifying and developing preclinical and translatable biomarkers in cardiovascular diseases. Dr. Cui received her Ph.D. in biology from Purdue University and completed her postdoctoral fellowship at Howard Hughes Medical Institute affiliated with the University of Michigan. Dr. Cui was the 17th SAPA President with the honor to be the first female President in the history of SAPA.

Pattie Drake  
VP Market Operations & Strategy Realization, Merck  
Pattie Drake is Vice President for Market Operations & Strategy Realization for Merck’s U.S. Market organization. In this role, Pattie leads Investment Analytics, Sales Operations, Marketing Operations and the Strategy Realization teams. This group is charged with developing and deploying new and innovative capabilities in the US market in support of the full portfolio – Primary Care & Women’s Health, Hospital & Specialty, Oncology and Vaccines. Pattie has an extensive U.S. Market background in roles of increasing responsibility across Sales, Marketing, Strategy and Operations. Pattie returns to the U.S. Market after two international assignments. In 2011, Pattie led The Americas Diversified Brands organization in Latin America headquartered in Mexico City, then moved to Canada to lead the Hospital and Specialty Business Unit and built the vertical Oncology Business Unit there. Most recently, Pattie was the Vice President of Sales for Primary Care and Vaccines in Canada. Pattie holds a Bachelor’s of Science degree in Marketing from Wichita State University (WSU) and is a Board member of WSU’s International Advisory Board.

Joseph Duffy, PhD  
Executive Director, External Discovery Chemistry, Merck  
Dr. Joseph Duffy is an Executive Director and Head of External Discovery Chemistry at Merck Research Laboratories in Kenilworth, New Jersey. He supervises a team of senior scientists deployed across the entire portfolio of small molecule Discovery Chemistry projects, with responsibility for the contribution and impact from international contract research resources. Joe’s work at Merck has included all phases of drug discovery, from lead identification and technology development (combinatorial chemistry) through clinical phase II/III candidate development teams. He has directed successful lead optimization efforts for multiple indications, resulting in clinical candidates and Investigational New Drug (IND) applications from both internal projects and international collaborative research with biotech organizations. His work has resulted in over 60 peer-reviewed research publications and granted or pending patent applications.

Joe received his Ph.D. in 1996 from Harvard University under the direction of Professor David Evans, where his research established methods and models for efficient synthesis of natural products using double stereodifferentiating aldol addition reactions. Joe is an alumnus of Kent State University (B.S. in chemistry) and of Eastman Kodak Research Labs Co-Op Program (research associate).
Michael Foley, PhD  
Director of Tri-I TDI and Sanders Innovation and Education Initiative

Dr. Foley is the Director of the Tri-I TDI, collaboration between MSKCC, The Rockefeller University, Weill Cornell Medicine and industrial partner, Takeda, to advance the groundbreaking discoveries of the academic institutions. Dr. Foley is an accomplished chemist and entrepreneur with more than 25 years of industry and academic experience. He has been scientific co-founder of five companies and one academic institute and has placed twelve single agent or combination drugs into clinical development. He was most recently the Director of the Chemical Biology Platform at the Broad Institute of Harvard and MIT, which successfully established over 150 high throughput screening development collaborations under his leadership. Dr. Foley previously worked at Bristol-Myers Squibb and GlaxoSmithKline, and obtained his PhD in chemistry at Harvard.

Dr. Zhihong Ge, PhD
Associate Vice President, Head of Global Development Quality, Merck

Dr. Zhihong Ge is an Associate Vice President, Head of Global Development Quality at Merck. Zhihong has over 20 years' experience in drug substance and CMC areas. She created and led a global drug substance Analytical Chemistry organization which spanned Analytical and Physical Chemistry disciplines and consisted of over one hundred scientists across six sites. Zhihong received her B.S. from Beijing University in 1987 and joined Merck in 1992 after completing her PhD at University of Washington. During her tenure at Merck, Zhihong participated in many development programs including marketed products Crixivan, Arcoxia, Isentress, Belsomar and Zepatier. In 1999, she created a Process Analytical Technology (PAT) group within the Process R&D and since then introduced numerous “first kind to Merck” PAT technologies to monitor, optimize and control drug substance synthetic processes. Zhihong authored or co-authored more than 30 publications. She has represented Merck on many PhRMA and International Consortium for Innovation and Quality (IQ) activities including PhRMA PAT Expert Working Group, PhRMA LD KIT (Limited Duration Key Issue Team) on Genotoxic Impurities, PhRMA ICH M7 Expert Working Group, IQ Analytical Leadership Group (ALG), API Starting Material Working Group and Specification Subteam.

Dahai Guo, MS, MBA
Chairman & CEO, PuraCap Pharmaceutical LLC

Mr. Dahai Guo is the Founder & CEO of PuraCap Pharmaceutical LLC., Empire Group LLC., Chairman & CEO of Humanwell PuraCap Pharmaceutical (Wuhan) Ltd., etc. He is currently managing six affiliate companies in US & China. Under Mr. Guo’s leadership, PuraCap Pharmaceutical & its affiliated companies are one of the leaders in specialty pharma & healthcare industry, who is developing, manufacturing and marketing broad range of Branded Rx, Generic Rx and OTC pharmaceutical products in US & the global markets. Currently, PuraCap & affiliates have over 80 different drugs and over 400 products selling in US, China, Canada and other countries. It has four US FDA inspected manufacturing and packaging facilities in US & China. Through his professional career, Mr. Guo has held senior positions in several multi-billion dollar global companies and also start-up companies in biotech, pharmaceutical and healthcare product industry. He had senior management position in global based public companies like Inverness Medical LLC. (now Aleer), Ansell Healthcare LLC, Roche Group). Mr. Guo has demonstrated strong leadership and broad experience in corporate management, M&A, sales & marketing, product development, global strategic planning and biotechnology research.

Before he came to US in mid 1990’s, Mr. Guo conducted molecular biology research at China’s top research institute, Chinese Academy of Sciences. He has introduced various bio-medical products into China market. Mr. Guo has MBA from Cornell University and M.S. of Biology from Rutgers University. He also completed distinguish Six-Sigma Black Belt training, awarded by America Society for Quality. Mr. Guo is current Chairman of BioKatalyst Corp, a non-profit organization whose invited-only members are the top management elites of Chinese Americans crossing healthcare industry.

Jiannming Jimmy Hao, PhD, JD, MBA  
Partner, Fox Rothschild LLP

Mr. Hao is a partner and U.S. patent attorney at Fox Rothschild LLP. With more than a decade of legal experience, Mr. Hao serves clients including Fortune 500 companies, startups, entrepreneurs, investors, and academic institutions on a broad range of legal issues, including patent, trademark, licensing, IP litigations, FDA, international, corporate, VC financing, and nonprofit. While focusing on preparation/prosecution of U.S. and foreign patents, he provides a full range of patent law services, including developing and managing worldwide patent portfolios, assisting in patent matters in connection with startups, strategic alliance, technology transfer, corporate transactions, freedom-to-operate, invalidity and non-infringement opinion analysis. Mr. Hao has provided representation to several notable business transactions, including Alexion Pharmaceuticals Inc.’s acquisition of Synageva BioPharma (valued at $8.4 billion), Humanwell Pharmaceutical Group Corporation’s acquisition of Epic Pharma ($550 million), BMS’s acquisition of Amira Pharmaceuticals ($475 million), licensing and collaboration deals involving major universities and companies.
Mr. Hao received a JD from Boston College Law School, a PhD from Columbia University, an MBA from Cornell University, and a BS from Nankai University. He is a Board Member and Founder of BioKatalyst, a non-profit organization of Chinese business leaders in commercial areas of biopharmaceutical industry.

Debbie Hart
President and CEO, BioNJ

Debbie Hart, founding President and CEO of BioNJ, is dedicated to the mission and work of BioNJ of ensuring a robust life sciences ecosystem in New Jersey. She worked alongside New Jersey’s biotechnology industry leaders to establish BioNJ in 1994 and has been pursuing this passion ever since.

Debbie is a founding board member and officer of OpportunityNJ, a non-profit organization working toward a strong and sustainable State economy; is on the board of the New Jersey Chamber of Commerce and is a member of the Board of Directors for Choose New Jersey. Additionally, Debbie has been active on the boards and committees of numerous government and academic institutions over her career.

Most recently, Debbie was named one of the world’s 100 Most Influential People in Biotechnology by Scientific American Worldview; as one of HudsonMod Magazine’s 2015 list of Women in Power; one of New Jersey’s top CEOs by COMMERCE Magazine; one of New Jersey’s 2015 Top 25 Leading Women Entrepreneurs & Business Owners by Leading Women Entrepreneurs and for the fifth time in 2017 to the NJBIZ Power 100, a listing of the 100 most influential people in New Jersey business.

Yiwu He, PhD, MBA
Senior Vice President of International Business, BGI

Former Senior Program Officer and Deputy Director, Global Health Discovery and Translational Sciences, Bill & Melinda Gates Foundation
Board Director, P4 Medicine Institute, Seattle, USA
Chair Professor, University of Science and Technology of China
Member, Board of Directors or Advisory Board, Several US biotech companies
Former Member of the Executive Board, International Society of Vaccine
Former Global Head and Senior Director, GlaxoSmithKline
Founder, Apomax Biolab Corp.
Founder, Precision Human Biolab, Inc.

David Ho, PhD
Professor, CEO of Aaron Diamond AIDS Research Center

David D. Ho, M.D. is the founding Scientific Director and CEO of the Aaron Diamond AIDS Research Center and the Irene Diamond Professor at The Rockefeller University. He received his degrees from the California Institute of Technology and Harvard Medical School. Dr. Ho has been at the forefront of AIDS research for 36 years, publishing over 400 papers. His elegant studies unveiled the dynamic nature of HIV replication and revolutionized our basic understanding of AIDS pathogenesis. This knowledge led Dr. Ho to champion combination antiretroviral therapy that has transformed an automatic death sentence into a manageable condition. He now devotes his time to novel approaches to block HIV transmission, including the engineering of potent anti-HIV antibodies. Dr. Ho has received fourteen honorary doctorates and has served on the governing boards of Harvard, MIT and Caltech. Moreover, he has been elected a member of the National Academy of Medicine (US) as well as the Chinese Academy of Engineering (PRC) and Academia Sinica (Taiwan). He was also named Time Magazine’s Man of the Year in 1996 and awarded a Presidential Medal by Bill Clinton in 2001.

Guanghui Hu, PhD
President & CEO, Admera Health, LLC

Dr. Guanghui Hu is the President and CEO of Admera Health. Prior to that, Dr. Hu acquired over 15 years of drug development, molecular diagnostics and management experience in the biopharmaceutical industry at companies including Merck and GlaxoSmithKline. Dr. Hu completed postdoctoral research at the University of California Los Angeles after earning his Ph.D. from Baylor College of Medicine, holds a Master of Science degree from the Chinese Academy of Sciences, and a Bachelor of Science degree from Tsinghua University.

Jamie Hu, PhD, JD
IP Counsel, Novo Nordisk Inc.

Dr. Hu is currently Intellectual Property Counsel at Novo Nordisk Inc. Dr. Hu’s major responsibilities include counseling stakeholders on diverse intellectual property matters and related corporate and legal issues; developing and maintaining comprehensive patent portfolios covering Novo Nordisk inventions and marketed products; and pursuing strategies and actions for strong patent protections.

Prior to joining Novo Nordisk in 2012, Dr. Hu practiced patent law at Fulbright & Jaworski LLP in New York City for four
years focusing on pharmaceutical and biological arts and litigation.

Dr. Hu holds a J.D. from Columbia Law School, a Ph.D. in Biochemistry from Purdue University and a B.S. from Nankai University.

Jennifer Hu (胡静珊), PhD
Partner, Qiming U.S. Healthcare Fund

Dr. Jing-Shan “Jennifer” Hu is Partner of the US Healthcare Fund of Qiming Venture Partners. Before Qiming, she was VP and Head of (External) Innovation Center China at Bayer Healthcare, responsible for building and managing partnerships for Global Drug Discovery with organizations in Greater China. Prior to that, she was Director of Licensing & External Research at Merck & Co (MSD) covering Greater China for Worldwide Licensing & External Research. She worked previously at Roche Palo Alto as Head of Functional Biology, at Affymetrix as Program Manager of Pharmacogenomics, and at Human Genome Sciences as Scientist of Protein Therapeutics. Dr. Hu obtained her post-doctoral training at Harvard Medical School, PhD from Univ. of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center, and BS degree in Biochemistry from Peking Univ. She is a board member of both BayHelix and Chinese-American BioPharma Society (CABS).

Jiangbin Hu, PhD
VP, Huahai Pharmaceutical

胡江滨博士现任华海药业有限公司副总经理，华海美国高级副总裁，国家“千人计划”特聘专家。负责浙江华海的项目立项与管理，制备研发，质量分析，申报注册，药政法规及临床医学。胡博士在加入华海之前，任美国药典委员会高级副总裁及美药典中华区首任总经理，从事药用原料，辅料，制剂及食品和膳食补充剂官方标准的建立，标准物质研发及质量体系认证。胡博士在美工作期间曾先后任职于罗氏，拜尔及诺华从事新药 CMC, 制剂开发及项目管理总监等工作。曾担任美中医药开发协会（SAPA）主席，美国质量协会（ASQ）全球专家顾问，美国药物信息协会DIA 中国区顾问及大会主席，中国药品企业家协会制剂国际化专家委员，《中国药学杂志》编委，北京大学国际药物工程管理硕士兼职论文指导教授及上海交大，浙江大学客座教授等职务。

Sean Hu, PhD, MBA
Sr. VP & Head of Consulting, GlobalData Inc.

Dr. Sean Hu is currently Senior Vice President and Head of Consulting in the USA for pharmaceutical and diagnostics industries at GlobalData PLC, a public company listed on the London Stock Exchange.

Dr. Hu brings more than two decades of broad experience in life science industries and academia. Aside from founding BioStrat Advisory LLC, for years he was a Managing Partner and Head of Biotech USA, both boutique life science strategy consultancies. His earlier career included IMS Consulting, SDG Life Sciences, AT Kearney, and hands-on industry experience at BMS, Illumina and CuraGen.

His broad consulting expertise spans across investment and licensing due diligence, product commercialization strategies and strategies for building and growing companies.

Dr. Hu is a world class expert in strategic decision-making, as well as a recognized thought leader in the field of personalized medicine strategy. He currently serves on the Editorial Board of the peer-reviewed journal Personalized Medicine.

As part of his extracurricular activities, he holds an Adjunct Professor position at the Chinese National Human Genome Center at Shanghai, Chinese Academy of Sciences, and Senior Advisor & Visiting Professor positions at the Beijing Genomics Institute.

Sean obtained his PhD from NYU and MBA from Wharton.

黄反之，MBA
分享投资联合创始人

拥有丰富的企业管理经验，曾任飞利浦消费通信公司财务负责人、沃尔玛中国公司财务总监、上市公司董事副总经理兼财务总监；9 年投资经验，投资超过 40 个项目，所投项目已有 4 家 IPO，多家挂牌新三板；

千人计划创业培训导师、中欧智慧医疗创业营导师、北大健康特训班导师；

中欧国际工商学院校友会理事、深圳校友会秘书长。

Jim Huang, PhD
Founder & CEO, Ascendia

Dr. Huang founded Ascendia in 2012 after fifteen years of pharmaceutical R&D and management experience at Pfizer, Baxter, AstraZeneca, and most recently Roche. He has led the formulation development efforts for the successful transition of several oral and parenteral dosage forms from discovery through formulation, manufacturing, technical transfer and ultimately commercialization. Dr. Huang holds a Ph.D. in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) where he worked with
Joseph B. Schwartz. Dr. Huang’s research interests are centered on improvement of solubility and dissolution, and controlled delivery of, poorly water soluble drugs through nano-emulsion and amorphous solid dispersion technologies. He has published numerous patents and papers and serves as reviewer for leading pharmaceutical journals; Currently, he is a member of American Association of Pharmaceutical Scientists (AAPS) and American Chemical Society (ACS).

**Kevin Huang, PhD**  
Chief of Staff, WuXi Biologics

Dr. Kevin Huang is Chief of Staff, Head of CEO Office and Corporate Strategy at WuXi Biologics. He helps formulate the WuXi Biologics’ strategic initiatives and facilitate their execution at corporate level, coordinates the company’s global expansion efforts in North America, Europe, and Asia. His team also manages corporate communication of the growing company and provide operation support to senior management. Before joining WuXi Biologics, Dr. Huang worked at Bristol-Myers Squibb on late stage process life cycle management, including the technology transfer, process validation, and commercial manufacturing of key biologics products. Prior to BMS, Dr. Huang has analytical R&D and process development experience at Amgen and Abbvie, and have worked at Morgan Stanley Hong Kong and Roland Berger Shanghai. Dr. Huang received his BS degree from Peking University and MS degree from University of Minnesota. He graduated from University of Illinois with PhD degree in Pharmaceutical Chemistry.

**Mathias Hukkelhoven, PhD**  
SVP, Regulator, BMS

Mathias Hukkelhoven, Ph.D., joined Bristol-Myers Squibb (BMS) in March 2010 as the Senior Vice President, Global Regulatory, Safety & Biometrics. He is responsible for setting regulatory strategy and driving execution of global regulatory, pharmacovigilance and biometrics plans for BMS. He is also responsible for leading the regulatory efforts across the product development and commercialization process to ensure optimal regulatory interactions at each step of the process – research and development, manufacturing, and commercialization. Since August 2016, he is also responsible for the R&D group in BMS China and the Clinical Pharmacology and Pharmacometrics group.

Prior to joining BMS, Math held the role of Chairman Portfolio Stewardship Board at Novartis Pharmaceuticals. From 2001 to 2009, he was the Senior Vice President, Global Head Drug Regulatory Affairs at Novartis. He joined Sandoz/Novartis in 1993 as the interim Corporate Head of Drug Regulatory Affairs in Basel, Switzerland. Math transferred to the United States in 1994 and held progressively responsible positions including Vice President, Head of US Drug Regulatory Affairs. Prior to Novartis, Math was the International Drug Regulatory Affairs Group Leader at Hoffmann La Roche. He first joined the pharmaceutical industry with Organon in the Netherlands, following a role as Research Fellow of the Dutch Cancer Society with the University of Nijmegen, The Netherlands. Math has a wealth of experience in global regulatory affairs and drug development, evidenced by his contribution to more than 35 NCEs over his career to date.

Math received his B.S. and Ph.D. honours degrees in Biology and Biochemistry from the University of Nijmegen, the Netherlands.

**Jeffrey S. Humphrey, PhD**  
President, CMO, Kyowa Kirin Pharmaceutical Development

Jeff Humphrey is an oncologist, Chief Medical Officer and President of Kyowa Kirin Pharmaceutical Development Inc. (KKD) based in Princeton, New Jersey. KKD is the American/European drug development subsidiary of Kyowa Hakko Kirin Company (KHK), a top-50 pharmaceutical company aspiring to become a Global Specialty Pharmaceutical company. As CMO/President, Jeff has oversight for US and European development of experimental therapeutics for oncology, neurology, immunology, and a rare genetic disorder. KKD is developing 2 first-in-class KHK compounds that are approved in Japan for T-cell Leukemia and Parkinson’s disease, respectively. Dr. Humphrey is the first American president of KKK, a member of KHK’s senior R&D decision-making committee, and a member of the CEO’s executive committee.

Dr. Humphrey previously served as VP of Oncology at both Bristol-Myers Squibb and Bayer Pharmaceuticals, and Clinical Exploratory Head of Oncology at Pfizer. Dr. Humphrey’s work over the past 20 years has included oversight or direct involvement in development of experimental and marketed oncology medicines, including submissions and/or launches of Sprycel, Ixempra, Yervoy, Eritux, Nexavar, Flotafur, and Taxol. He has developed specialized knowledge in anti-angiogenesis, companion diagnostics, and immuno-oncology during his career.

**Sam Kay, CFA**  
Associate Director, US Strategy, Partnering & Operations, Novartis

Sam Kay is currently an Associate Director of US Strategy, Partnering & Operations at Novartis. In this role, he manages the strategy and operations for US Oncology and is responsible for business collaboration across enterprise. Prior to joining US Oncology, Sam Kay held a global role as the Global Business Analytic lead responsible for generating
insight & analytic in several therapeutic area across all product lifecycle. He also worked in several Canadian biotech companies in multiple diverse roles. He received his Bachelor degree from McGill University in Microbiology & Immunology. He is also a CFA® charterholder.

Michael Keyoung, MD, PhD
Managing Director and Head of North America, C-Bridge Capital

H. Michael Keyoung, MD, PhD is a physician, investor and executive with 20 years of experience. He is Managing Director and Head of N. America for C-Bridge Capital, China-centric focused healthcare investment firm. He currently serves on the Board of Imab, portfolio company of C-Bridge. Dr. Keyoung is founding Managing Partner of Portola Capital Partners and was President and CEO of Genexine Inc, KOSDAQ listed biotech company with partnerships with Tasly and Fosun Pharmas as well as Merck for Keytruda combo trial in cervical cancer.

Previously, Dr. Keyoung was President of Catalyst Biosciences (NASDAQ: CBIO). Prior to Catalyst, Dr. Keyoung was Managing Director, Portfolio Manager and Head of Pan-Asia for US investment firm, Burnil & Company. Throughout his career, he has advised leading MNC companies in their regional expansion to Asia or global drug development, commercial strategies and partnerships. Dr. Keyoung was instrumental in creation of Samsung Bioepis, JV between Samsung and Biogen.

Dr. Keyoung received Medical Doctorate and Ph.D. from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center as MSTP scholar. Dr. Keyoung was a HHMI Research fellow, biomedical fellow at Rockefeller University and received his clinical surgical training at the University of California, San Francisco.

Wilson Lee, MBA
Director of US for Sino-Sichuan (Chengdu) Innovation Park Development Co.

Wilson Lee is the Director, United States, of the Sino-Sichuan (Chengdu) Innovation Park Development Co. - a joint venture between Sichuan and Singapore. The company is responsible for the development of the Singapore-Sichuan Hi-Tech Innovation Park (SSCIP), located in Chengdu. Wilson heads SSCIP's office for international investment promotion in the United States.

Wilson has 10 years of experience in assisting Fortune 500 and other international companies to break into new markets in the United States and Asia. Prior to joining SSCIP in 2014, Wilson spent over 6 years working in Singapore where he held international business development positions at Gerson Lehrman Group and Singapore Economic Development Board. In these roles, Wilson was responsible for helping international companies expand their global presence in Southeast Asia.

Wilson graduated from Nanyang Technological University with a Bachelor's degree (Honors) in Electrical and Electronic Engineering and holds an MBA from California State University-Fullerton.

Feng Li, MS
Founding Partner, FreeS Fund

Feng Li is the Founding Partner of FreeS Fund.

- Investment focus: Deep technology, Healthcare, TMT, online education and consumption upgrade
- Investment Case: Uber Global, Unity, CreditEase, Three Squirrels, Bilibili, Ripple Labs, XtalPi, Novita, Prosper
- Previously as a partner at IDG-Accel, he led investments on a series of successful projects, including CreditEase, Zhubajie, Prosper, Three Squirrels, Tongbanjie, Didapinche, Bilibili, Cointbase, Changingedu, Dig Fortune, Helijia, Yodo Fortune, FraudMetrix, Lulishou, Ripple Labs, Wecash, Jiang Xiaobai, Hstyle, bairong, and bairong. Among them, CreditEase went public in 2015, Zhubajie and Prosper successfully joined Billion Dollar Club. The return of investment at seed stage for Three Squirrels, Tongbanjie, and Wangli Finance Group are now up to 50 times.
- Feng led the establishment of IDG-Accel’s post-investment service system, providing help to early stage startups.
- Services include public relations, marketing, and human resources. He promoted topic investment strategy including Internet brand, Fintech, Biotech, the 90s entrepreneurs project, C2C of O2O and economy sharing approach.
- Feng obtained B.S. in Chemistry from Peking University, and M.S. in Chemistry from University of Rochester.

Ji Li, PhD
EVP, Global Head of Business Development, BeiGene Ltd.

Dr. Ji Li has more than 20 years of business development and R&D experience in the biopharma industry. He is currently Executive VP and Global Head of BD at BeiGene where he oversees the company’s partnering activities worldwide. Prior to BeiGene, Dr. Li served as VP of BD&L at Merck, where he was responsible for BD activities of all late-stage inbound and outbound opportunities globally. Prior to Merck, Dr. Li was Executive Licensing Director, External R&D at Amgen where he led the company’s product search and evaluation BD team. Earlier in his career, Dr. Li was key
Tatiana Litvin-Vechnyak, PhD  
Executive Director, Licensing & IP, Rutgers University  
Tatiana is the Executive Director of Licensing & IP at the Office of Research Commercialization of Rutgers University. Previously she was the Director of Biomedical and Life Sciences Licensing, and before the merger with Rutgers University in 2013, she was the Associate Director of the Office of Technology and Business Development at UMDNJ. Before joining UMDNJ/Rutgers, she worked at the Office of Technology Transfer and Business Development at Mount Sinai School of Medicine as a Senior Licensing Associate. Tatiana holds a Ph.D. in Pharmacology from the Weill Cornell Graduate School of the Biomedical Sciences, recently taught a course on commercializing innovation for the Rutgers Graduate School of Biomedical Sciences and is a Registered Patent Agent with the US Patent and Trademark Office.

Hong Liu, PhD, JD  
Senior Corporate Counsel, Bristol-Myers Squibb  
Hong Liu is a Senior Corporate Counsel of Bristol-Myers Squibb Company mainly responsible for patent prosecution and IP strategy work. Prior to joining BMS, he had worked as an associate at Cooley LLP and as a Patent Examiner in the United States Patent and Trade Office. He obtained a Ph.D. degree in pharmacology from Columbia University College of Physicians and Surgeons in 1998 and a J.D. degree from Georgetown University Law Center in 2004.

Hongbo Lu, PhD, MBA  
Partner, LAV (Lilly Asia Ventures)  
Dr. Hongbo Lu currently is a partner at Lilly Asia Ventures, a healthcare-focused investment firm with over USD$1.2 billion AUM. Previously, Dr. Lu was with Orbimed Advisors, serving as its Managing Director in Asia, responsible for over $500m public equity investment portfolio in emerging markets. Dr. Lu has also led private equity investments and served as board of directors of private and public companies. Dr. Lu has over 15 years of investment and operational experience in the healthcare industry, including her tenures at Orbimed, Piper Jaffray & Co. and life science start-up Zymyx. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University in China.

Theresa Mullin, PhD  
Director, Office of strategic program, FDA/CDER and Chair of ICH management committee, FDA/CDER  
First serving as FDA Associate Commissioner for Planning, and later joining CDER as Director of the Office of Strategic Programs, Dr. Mullin has continually worked to modernize regulatory operations and strategically position the agency for the future. She has served in a variety of roles including as FDA lead negotiator in the past 4 cycles of PDUFA reauthorization and the past 2 cycles of BSUFA, leading the FDA delegation to ICH negotiating the future structure and operation of international regulatory harmonization, and initiating and leading FDA’s Patient Focused Drug Development effort. Since joining FDA Dr. Mullin has received recognition for her work including the SES Presidential Rank Award for Meritorious Service in 2006 and
Kimberly Nearing, MS
Managing Director and Head of Life Sciences, Cedrus Group

Kimberly Nearing is the Managing Director & Head of Life Sciences at the Cedrus Group, a global boutique investment firm. Kimberly has over 22 years of life sciences experience, including as a senior manager, investor, investment banker and consultant.

In her current role, at Cedrus, she leads and manages two investment banking groups, one in the firm’s headquarters in Hong Kong and the other in its Shanghai office. Previously, Kimberly has managed a late stage biotechnology venture capital fund in San Francisco Bay Area. She has also held various senior management positions at Amgen, Merck, and IBM Healthcare, also in the U.S. Her experience and networks in the life sciences industry are primarily in the U.S., Europe, and China.

Kimberly received a Master of Science (MSc) with Honors from Harvard University (having attended both the Harvard Business School and the Harvard T.H. Chan School of Public Health) and a Bachelor of Arts (BA) with Distinction from the University of Michigan in Economics and English. She splits her time between New York, Hong Kong, and Shanghai. Kimberly’s affiliations include Rostropovich-Vishnevskaya Foundation (board member); Sino-American Pharmaceutical Professional Association (member); and Women in BIO (member).

Gerard P. Norton, PhD, JD
Partner, Chair Intellectual Property Practice, Fox Rothschild LLP

Gerard P. Norton, Ph.D., is a partner at Fox Rothschild LLP and Chair of the firm’s Intellectual Property Litigation practice group. Gerry is also the former chair of the Intellectual Property Department. He has extensive experience litigating complex matters pertaining to patents, trademarks, copyrights, trade secrets and breach of contract. Gerry has represented pharmaceutical companies in a wide range of litigation matters, including a patent dispute involving a question of first impression before the Federal Circuit.

Prior to joining Fox, Gerry was a named partner of an intellectual property law firm in New Jersey, and was a patent litigator for 10 years at Rogers & Wells and at Clifford Chance in New York. A graduate of Fordham University School of Law, Gerry earned a Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine and a B.A. in biology at Fordham College. He held a post-doctoral fellowship with Merck & Co. Inc.

Wendy Pan, PhD, JD
Partner, SIDLEY AUSTIN LLP

Wenseng “Wendy” Pan focuses on mergers and acquisitions, technology-based transactions and strategic partnerships, especially in the life sciences industry and in cross-border settings. Her clients rely on her as an incredibly intelligent lawyer who finds solutions for her clients. She is very personable and responsive – very good to deal with. I recommend her highly. She is one of the few lawyers in China on whom I rely, she understands both the Chinese and US markets. She is a leader of the firm’s life sciences and technology transactions in Asia. She is a frequent speaker on Chinese outbound M&As and cross-border life sciences transactions. She is an active figure in the US/China life sciences community and has been recognized as a “deal broker” by BioWorld Today.

She has advised private equity firms in leveraged buyouts and has represented financial institutions, technology, media and telecoms (TMT), biopharmaceutical, manufacturing, publishing, electronics companies and retail chains in stock and/or cash acquisitions, mergers, tender offers and going-private transactions. Wendy has advised on mergers and acquisitions transactions with an aggregate value over US$10 billion. She also represents VC firms and start-up and growth stage companies in venture capital and pre-IPO financings. Wendy represented BGI-Shenzhen in its acquisition of a US Nasdaq company, which is the first successful acquisition of a US public company by a Chinese company.

Wendy has advised life sciences companies and technology companies in structuring and negotiating complex IP-based transactions and other commercial arrangements. Her practice covers product and technology licensing, strategic partnerships and joint venture formations and research, product development and commercialization collaborations as well as mergers and acquisitions and private investments. As a former scientist and a registered U.S. patent attorney, Wendy possesses a unique set of skills for counseling her clients on intellectual property related issues in non-contentious settings.
Grace Qiao, PhD
Bioinformatics Analyst, GENEWIZ

Grace Qiao is a bioinformatics analyst at GENEWIZ, a global contract research organization with a focus on genomics services. She earned her B.S. degree in biological engineering from Shanghai Jiao Tong University, Shanghai, and her Ph.D. in immunology from the University of Michigan, Ann Arbor. She completed her postdoc training at the Hospital for Special Surgery in New York before joining GENEWIZ in 2015.

At GENEWIZ, she is a major contributor in establishing the immune repertoire sequencing service. She plays a critical role in wet lab and dry lab development, as well as performing market research. In addition, Dr. Qiao has developed multiple bioinformatics pipelines while at GENEWIZ. Her focus extends to the application of high throughput sequencing in antibody discovery, primarily in market and product assessment, as well as project management.

Shahnam Sharareh, PharmD, RAC
Partner, Fox Rothschild LLP

A seasoned intellectual property attorney at the national law firm of Fox Rothschild LLP, Shahnam has experience in preparing and prosecuting U.S. and international patent applications in a wide range of technologies, including chemistry, pharmaceuticals, pharmacology, biotechnology, medical diagnostic and cosmetic products and nanotechnology. His practice also includes counseling clients; preparing patentability, validity and infringement opinions; patent reissue and reexamination practice; and drafting intellectual property agreements.

Shahnam is a Regulatory Affairs Certified (RAC) professional and advises clients on FDA regulatory matters, marketing and advertising strategies for drug, food and dietary supplement products.

Prior to joining the firm, Shahnam was a Patent Examiner with the U.S. Patent and Trademark Office, where he managed an extensive portfolio including pharmaceutical and diagnostic compounds and compositions. He also served as a research associate with Kendle International, where he monitored FDA required regulatory and clinical data during the Celecoxib clinical trials.

In addition to his juris doctor degree from the University of Maryland School of Law, Shahnam also holds a doctorate in pharmacy from the University of Illinois at Chicago and a Bachelor of Science in pharmacy from the University of New Mexico.

Jing Sun, PhD
Asia Pac IP Lead, Bristol-Myers Squibb Company

Jing Sun, Ph.D., Asia Pac IP Lead and Senior Patent Agent, Bristol-Myers Squibb Company. Jing has worked in pharmaceutical industry for over 24 years, including 16 years with BMS. She was the IP Head of China Novartis Institute for BioMedical Research Company from 2014 to 2016. Jing has extensive experience in preparing and prosecuting small molecule pharmaceutical patent applications to capture innovation throughout the lifecycle of pharmaceutical products including protecting new chemical entities, methods of treatment and formulations.

Weiyong Sun, MD, PhD, MBA
Senior Director, External Scientific Affairs, Global BD&L, Daiichi Sankyo Group

Dr. Weiyong Sun is currently Senior Director, External Scientific Affairs, Global Business Development and Licensing at Daiichi Sankyo Group. He joined Daiichi Sankyo Japan in April 2002. He was involved in a broad range of R&D activities from target discovery to clinical development of a number of anti-diabetes drugs. In October 2007, Dr. Sun was elected to be assigned to work for Daiichi Sankyo Research Institute in the U.S. He was responsible for identifying and evaluating in-licensing, partnering and research collaboration opportunities. His current focus is in Thrombosis & Thrombolysis, Pain, Cardio-Renal, Ophthalmology and Rare Disease. Dr. Sun received an M.D. from Beijing Medical University (now Peking University Medical School), a Ph.D. in Biochemistry from the University of Tokyo and an MBA from Columbia Business School. He was a postdoctoral fellow in the Blood Research Institute, Medical College of Wisconsin.

Lauren Supraner
President, CAL Learning

Lauren Supraner is the founder and president of CAL Learning, an intercultural communication consulting and training company. She helps multicultural organizations leverage and maximize their diverse talent through language and culture training programs. Lauren has over 20 years’ experience in language and culture training, assessment, and program development. She coaches foreign-born professionals in accent reduction, business English, and American workplace culture, and has helped thousands in the pharma/biotech, IT, healthcare, and other industries in developing their language and culture skills. Her clients include: Regeneron, IBM, Center for Disease Control and Prevention, Novartis, Educational Commission for Foreign Medical Graduates, Catalent, and Columbia University. Lauren has lived and worked in Japan and Thailand, and holds an MA in TESOL from Columbia University. Before
founding CAL Learning, Lauren was the director of Training and Workforce Development at Pace University in New York, where she developed programs for adult education as well as corporate training initiatives.

Jonathan Jiong Tang, MBA, CFA
Senior Manager, Empire Valuation Consultants

Jonathan is a Senior Manager at Empire Valuation Consultants. He has over a decade of experience in valuations related to complex securities, intangible assets, mergers and acquisitions, and tax planning. He has managed numerous engagements for financial reporting purposes, including ASC 820 (Fair Value Measurements), ASC 805 (Business Combination), ASC 718 (Stock Compensation), and Impairment Testing (ASC 350/360). He has also performed many valuations for tax reporting, acquisition and divestiture, transfer pricing, ESOP, and general corporate planning purposes.

Prior to joining Empire, Jonathan was a senior engineer in the telecommunication industry, at Lucent Technologies and Conexant Systems, where he designed Very Large Scale Integration Systems on a Chip for Digital Signal Processing applications.

Mark Tang, PhD, MPH
Managing Director

唐马克博士现任纽约 Good Health Capital 总监和医药健康风险和私募基金投资人。作为华尔街知名的华人生物技术金融家和企业家，唐博士的从业经验长达二十年。他是在大陆留学中最早在华尔街从事生物科技投资基金业务的华人之一，也是拓展亚洲生物科技创新产业的先驱。唐博士曾就职于投行摩根斯坦利和潘恩韦伯(联合瑞士银行)。他作为创始人之-创建了《生物医药投资通信》和2家高科技公司并将其成功兼并退出，并撰写了《生物医药投资必读》一书。唐博士就读于加州大学和哈佛大学。

Mark Tang is a managing director of Good Health Capital, managing a healthcare PE fund. Dr. Tang was a former faculty and biotech director of Rutgers Business School, as well as a former biotech analyst and I-banker. He attended Univ. of California and Harvard Chan School.

Weikang Tao, PhD
VP and CEO of R&D Centers, Jiangsu Hengrui Medicine Co, LTD

Dr. Weikang Tao has served as vice president of Jiangsu Hengrui Medicine Co., LTD. and the CEO of R&D Centers since Feb. 2014. In this position, he has led the R&D of innovative therapeutics, ranging from small molecule drugs, therapeutic antibodies to antibody-drug conjugates and discovered and developed a dozen small molecule drugs and biologics into clinical trials both in China and in the US. Formerly, he served as a vice president and the head of biology and pharmacology at Shanghai Chempartner Co., Ltd, a publicly traded company at that time, taking charge of the departments of biology, pharmacology, pathology and translational medicine and overseeing drug R&D programs in different therapeutic areas through collaboration with multiple global pharmaceutical companies and biotech. From 2000 to 2012, he conducted drug R&D at Merck & Co., Inc. in the US as a project leader and functional head, where he led a number of projects and delivered several compounds into clinical phase I trials. Dr. Tao has published multiple research papers in premier life science journals and he is the holder of many issued and pending patents in drug discovery. He obtained a Ph.D. degree in Molecular & Cell Biology from University of Medicine & Dentistry of New Jersey. He was a post-doctoral fellow in cancer cell biology at Princeton University.

Dr. Lawrence Tian is the Founder and Chairman of China Entrepreneurs Forum and China-U.S. Business Leaders Roundtable. As a core organizer of various high-end meeting for entrepreneurs of both countries, Dr. Tian is an influential figure in the Sino-China business scene and has extensive social influence. He is also the Vice Chairman of Investment Committee of China Pharmaceutical Industry Research and Development Association.

Lawrence Tian, PhD
Founding Partner, YuanMing Capital

Dr. Lawrence Tian is a Founding Partner of YuanMing Capital. YuanMing Capital is a healthcare specialty fund focusing on China-US cross border investments with offices in Beijing and New York City. The fund invests in therapeutics, medical devices, diagnostics as well as healthcare service companies based in US and/or China. Prior to founding YuanMing Capital, Dr. Tian established China International Futures Corporation and served as Chairman of China Chengtong Group. Since 2010, Dr. Tian has been committed to promoting China's capital investment into US life science innovative companies, and has accumulated solid experiences and an outstanding track record. He has successfully invested in a dozen of leading biopharma companies including BeiGene, Ascentage Pharma, Mevion Medical Systems, Pharmacodia and CF PharmTech.

Dr. Tian is the Founder and Chairman of China Entrepreneurs Forum and China-U.S. Business Leaders Roundtable. As a core organizer of various high-end meeting for entrepreneurs of both countries, Dr. Tian is an influential figure in the Sino-China business scene and has extensive social influence. He is also the Vice Chairman of Investment Committee of China Pharmaceutical Industry Research and Development Association.
Dr. Tian obtained his master’s degree and doctoral degree in Wuhan University, he was awarded by the China highest prize for economics: The China Economics Theory Innovation Award.

Francis L. Tse, PhD
Vice President & CSO, New Jersey Site Head, WuXi AppTec LTD

Francis L. Tse received the B.S., M.S., and Ph.D. degrees from the University of Wisconsin-Madison. Upon graduation he served as Assistant Professor of Pharmacy at Rutgers University. Prior to joining WuXi AppTec, Dr. Tse was Vice President of Drug Metabolism & Bioanalytics at Novartis Pharma where he has cumulated over the years a wealth of experience in pharmaceutical development. He has published over 130 research articles and six books, including “Handbook of LC-MS Bioanalysis” (Wiley, 2013) which has been translated into Chinese (Science Press, Beijing, 2017). Dr. Tse served on the Board of Directors of International Consortium for Innovation and Quality in Pharmaceutical Development (IQC), and is a Fellow of American Association of Pharmaceutical Scientists (AAPPS), Academy of Pharmaceutical Research and Science (APRS), and American College of Clinical Pharmacology (ACCP). He is a recipient of the prestigious 2006 Outstanding 50 Asian Americans in Business Award.

David Wang, MBA
Partner, the Maverick Capital Co., Ltd.

- M.S degrees from Tsinghua Univ. and Rutgers Univ.; MBA degree from Carnegie Mellon Univ.
- As a Partner of the Beijing Maverick Capital Management Co., Ltd., I am currently in charge of early stage startup project investment, mainly focused on both Healthcare and TMT fields. Led numerous early stage project investments in AI projects, intelligent hardware, SaaS, and other high-tech projects;
- Worked for Bristol-Myers Squibb Co. (BMS) as a Research Scientist in the Drug Discovery department and an internal consultant in the Strategy and Operations group; Did MBA internship at IBD of the Credit Suisse Founder Securities Company in Beijing; The head of the Beijing business department of Shanghai Tebon Fund Management Co., Ltd.;
- Served on the Judging Panel of the Heilongjiang satellite TV “王牌创客营” program; The Judging Panel of the Zhongguancun U30 entrepreneurship competition.

In late 90s, Dr. Jin Wang joined Paramount Capital, served as an Asia/Great China Regional Director, he also provided value-added service as a venture partner & executive for a portfolio company, PolaRx Biopharma. After that, he became a China Head for business & clinical development of a public company, Cell Therapeutic, Inc. In 2002, he returned to China, started his own VC firm, MCG Group and invested more than 20 biotech or healthcare related companies in China and US. He is a co-founder of SAPA. In his early research career, he worked for Worcester foundation and Roche Pharmaceutical. He obtained his BS from Zhejiang University and Ph.D.in Biomedicine from WPI in US.

Sally Wang, JD, MPH
CEO & Co-founder, DocFlight

Sally Wang is a health tech entrepreneur, with an interdisciplinary career in healthcare that spans law, policy, business, science & technology. She is the CEO & Co-founder of DocFlight, an international telemedicine startup connecting Chinese patients with top US doctors. Previously, she was Chief Strategy Officer, EVP of IP & Regulatory at a healthcare startup, valued at $100 million. She clerked for a federal judge, practiced at a premier law firm, worked on healthcare issues of national importance at US Senate and Food and Drug Administration. Sally has written and spoken on numerous aspects of technology and entrepreneurship, digital health, healthcare and IP law. She co-authored American Bar Association’s book on healthcare IT law. She has spoken at General Assembly, BluePrint Health, Harvard, Yale, MIT, Wharton, Food and Drug Law Institute. Sally has a JD, MPH and A.B. in Biology, all from Harvard.

Don Warkentin
Director of Training, Dale Carnegie Training

Don Warkentin is the Director of Training for Dale Carnegie Training of Central & Southern New Jersey. He delivers customized training for clients and manages a team of talented trainers. He consistently exceeds client expectations and has lead projects that have grown from small engagements all the way up to global roll outs of training.

Don worked with General Electric’s Healthcare division where he was a Senior Trainer and achieved certifications in a range of GE professional skills and leadership programs. His role involved extensive travel throughout North America delivering these programs and serving as a liaison for leadership development. He also worked for Shiseido
America where Don was responsible for a wide range of training and development needs from designing the new employee orientation process to ensuring that the necessary regulatory training was completed and documented. As the key training professional responsible for training needs, he gained broad exposure to a manufacturing environment and helped the organization achieve certification to the ISO 9000/14000 standards.

James S. Yan, PhD, MD, DABT
Executive Vice President, Head of Early Development and Drug Safety, ZAI Lab

Dr. James Yan is Executive Vice President in ZAI Lab, where he is heading the Early Development and Drug Safety to support drug research and development process from late-stage discovery through registration. James has over 25 years of research experience in academics and the pharmaceutical industry with extensive training in the fields of Pharmacology, Toxicology, Molecular Biology, and Oncology. He also has over 15 years of experience in non-clinical drug development of both small molecules and biologics in Pharmaceutical industry. James is well versed in multiple industry regulations such as FDA, EMA, CFDA, OECD, ICH as well as other international guidelines for drug development. Prior to ZAI Lab, James was the Head of Covance Early Development (ED) Shanghai Site, where he was responsible for all the business and successfully led the team to turn the business to profit with strong foundation of leadership being established. Dr. Yan started his career in Pharmaceutical industry with Pharmacia/Pfizer and was responsible for the development of a variety of new technologies for non-clinical drug safety assessments. Then he moved in Hospira, where he headed toxicology group and focused on toxicology programs supporting drug development and regulatory submissions. In 2009, James moved back to China and serviced as the Head of Drug Safety Evaluation and Program Management in Hutchison MediPharma. Over the course of his career, he was involved in IND and NDA filings for multiple drug candidates and gained substantial experience working with global regulatory agencies, including the US FDA, EMA, Australia TGA and China FDA (CFDA).

Dr. Yan received PhD degree from Peking Union Medical University and did his post-doctoral training at the Ben-May Institute for Cancer Research, University of Chicago. He is a Diplomate of the American Board of Toxicology (DABT).

Jijun Xing, PhD
Science and Technology Counselor in Chinese Consulate-General in New York

He received a bachelor degree of engineering, Tianjing University, a master degree in economics, People’s University of China and a PhD in administrative management, Huazhong S&T University. Dr. Xing has years of experience since 1990 in managing and facilitating international scientific and technological cooperation. He served in Chinese Embassies in Norway and the Netherlands, Director of Asia and Africa and Director of Europe in the Chinese Ministry of Science and Technology (MOST). Before taking the current position, Dr. Xing served China Science and Technology Exchange Center as Deputy Director General covering governmental and non-governmental cooperation in science and technology, technology transfer and academic exchanges. His personal academic interest includes low carbon development technologies and low cost health technologies etc. Dr. Xing is now still a strategic evaluation expert for international cooperation under European Horizon 2020 program.

James Jianguo Yang, PhD
CEO, Abpro China

Dr. James (Jianguo) Yang has over 20-year extensive experience in biopharma industry. Currently, Dr. Yang is President / CEO Abpro-China ( Abpro, a Biotech company based in Boston area, USA). Before joining Abpro, Dr. Yang was CSO / VP Biologics in Qilu Pharmaceuticals, and also had scientific leadership positions in several global 500 pharmaceutical companies, including in Abbott Lab Pharma Division (current AbbVie), MedImmune /AstraZeneca, Genzyme / Sanofi. Dr. Yang has published numerous patents and scientific papers, and is an editor advisor and reviewer for Bioprocess International (Journal), and Executive Director, Sino-America Pharmaceutical Association-NE (2012-2014), and reviewer for several scientific journals. As international recognized scientist in biopharma Industry, Dr. Yang is a frequently-invited speaker for international biotech/biopharma conferences. Dr. Yang got his Ph.D. in cell/molecular biology from Illinois Institute of Technology, USA.

John Junzhi Yao, PhD
CEO, TC Scientific

Dr John Junghi Yao is founder and CEO of TC Scientific, a chemistry centric leading CRO in Edmonton, Alberta Canada. Dr. Yao co-founded TC Scientific in 2009 and has over 20 years experience in organic synthesis and the chemical CRO business. He has worked with wide variety of companies ranging from, virtual to large biotech and Pharmaceutical companies.

Shirley Ying
VP, Head of Enterprise Data Strategy and Analytics, Komodo Health

A highly energetic and passionate strategic executive with in-depth knowledge of marketing insights / big data / real word data and analytics in life science. With a decade of track...
Betty Yu, CFA
Senior Vice President, China Merchants Bank New York

Before joining CMBNY, Betty was a Managing Director at Knights Group (formerly, Knights Investment Group), a New York headquartered direct investment and advisory firm with additional offices in China. She has been overseeing cross-border direct investment and M&A/strategic investment advisory, client and partner relationships, daily operations and business development. In her previous roles as an Executive Director at a cross-border investment advisory firm Balloch Group, and a Vice President with the Mergers & Acquisitions Group/Investment Banking Department at the leading Japanese investment bank Daiwa Securities America, she was active in originations, and led the team in executing cross-border M&A transactions. She was responsible for sourcing Asia - North America advisory engagements, advising international clients on corporate development strategies, and has executed transactions across different world markets including equity sale, subsidiary divestiture, acquisitions, strategic minority investments, secondary market divestiture of private equity portfolios, as well as JV/alliance strategies. For example, she executed Kobayashi Pharmaceutical’s acquisition of U.S. based HotHands’ manufacturer HeatMax, Revere Group’s equity sale to NTT Data, Softbank’s U.S. direct investment portfolio sale, Fujitsu Consulting’s acquisitions, Fukuda Denshi’s France based subsidiary divestiture, to name a few. Prior to that, she worked in New York for Lehman Brothers, Citbank/Citigroup, and as a consultant at Goldman Sachs in various capacities throughout the earlier years of her career.

Betty holds a Bachelor’s degree in International Business Law from Fudan University, Shanghai, China, and an MBA degree in Finance from Baruch College, New York. She is a Chartered Financial Analyst (CFA). Fluent in both Mandarin and English while having spent her life in both China and the U.S., she loves passionately and understands deeply both cultures. She was filmed in Beijing Television (BTV)’s 2007 documentary “Chinese Women on Wall Street”, and China Central Television (CCTV)’s 2007 – 2008 multiple-series documentary “Oceans Away”.  

Jianda Yuan, MD, PhD
Director of Translational Oncology at Early Oncology Development, Merck

Dr. Yuan currently is the Director of Translational Oncology at Early Oncology Development Department of Merck Research Laboratory. Before he joined Merck in February, 2016, He established and led the translational biomarker research at Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center in the past decade. His research interest is translational medicine and biomarker discovery for immune checkpoint blockade immunotherapy with approximately 70 peer-reviewed articles, including publication in Science, NEJM, Nature Medicine, Nature Immunology, PNAS, Blood, Journal of Immunology, Clinical Cancer Research and Journal Immunotherapy of Cancer. He is a member of SITC, AACR and ASCO. Dr. Yuan is an Associate Editor of the Journal Immunotherapy of Cancer. He served as a Member of the steering committee for the CRI-CIC from 2006 to 2011. He is Group Chair of the SITC Biomarker Task Force.

Dan Zhang, MD, MPH
Executive Chairman, Fountain Medical Development Ltd.

Dr. Dan Zhang is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with 1400 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia and USA.

Dr. Zhang was the Head of Clinical Development at Sigma-Tau Research Inc. He was a vice president at the Quintiles Transnational Corp. and the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd.,

Dr. Zhang is a member of grant application review committee for National Key Drug Development Fund of China, and is also a consultant for the China Food and Drug Administration (CFDA). He is chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China, and was the secretary-general (2011-2017) of the Association “Thousand Talent” Expert

Tong Zhang, PhD
SVP, Head of Corporate BD, WuXi AppTec

Dr. Tong Zhang is VP, head of Corporate BD at WuXi AppTec. In this role he is responsible for strategic partnership and M&A to strengthen WuXi’s comprehensive platform supporting R&D and manufacturing for pharmaceutical, medical device, cell and gene therapy, diagnostics and genomics products and services.
Prior to WuXi as head of Business Development for MSD China, he led BD activities for including M&A, investment and commercial partnership. Previously Tong was pan-regional lead for Emerging Market business development team at Merck & Co., with responsibilities for sourcing and executing BD activities across emerging markets and an emphasis on China.

Tong was head of Business Development at EKR Therapeutics, a VC-backed specialty pharmaceutical company in the US, where he led several acquisition, licensing and collaboration deals, valued at over $150M. Tong also had investment experience as a Director at ESP Equity Partners, a private investment company focused on biopharmaceutical industry in the US and China, and as an equity analyst covering the US pharmaceutical industry for Credit Suisse in New York. Tong worked as a consultant for ISO HealthCare Consulting (now part of the Monitor Group) and Defined Health, leading strategy consulting firms in the biopharmaceutical industry.

Tong received his Ph.D. in Biology from Columbia University and a B.S. degree in Biology from Wuhan University in China. He also performed post-doctoral research at Sloan-Kettering Cancer Center in New York in the lab of Nobel Laureate Dr. James Rothman.

Zhongda Zhang, PhD
VP of Pharmaron
BS, MS from China
PhD, University Bern, Switzerland
Postdoc, University Pennsylvania
Research Associate, University Pennsylvania
Biomol International, 1997 -2000
ENZO Life Sciences, 2001 -2011
Pharmaron INC. Since 2011
2008 President of SAPA-GP

Wei Zhao (赵巍), PhD
Senior Associate, 6 Dimensions Capital
Wei Zhao joined WuXi Healthcare Ventures (now 6 Dimensions Capital) in 2016. Prior to that, Wei was a Senior Life Sciences Specialist at L.E.K. Consulting Boston office, and a postdoctoral fellow at Mass. Eye and Ear Infirmary and Harvard Medical School. Wei obtained his Ph.D. in Neuroscience from Northwestern University, and B.S. from Tsinghua University.

Lihua Zheng, PhD, JD
Partner, Liu Zheng Chen & Hoffman LLP

Zhongda Zhang律师是美国成美律师事务所创始合伙人，执业范围包括跨国技术交易，专利组合管理，风险投资，借壳上市等。最近代表海普瑞制药对OncoQuest股权投资及合资公司组建，重庆华邦健康对Aridis股权投资及合资公司组建，复星医药从美国Rockwell Medical获取中国区药物销售权，恒力国际对Novus, Haydale等的股权投资及合资公司组建等。郑律师拥有法律（福特汉姆），生物医学（贝勒医学院）双博士学位，本科毕业于复旦大学，即是纽约州又是美国专利商标局执业律师。

Jin Zhu, PhD, JD
Attorney, Fox Rothschild, LLC

Jin Zhu is a patent attorney whose work involves evaluating and building market exclusivity for pharmaceutical and chemical companies. With expertise in chemistry and drug discovery, Jin’s practice at Fox Rothschild focuses on patent litigation, IP exclusivity analysis, as well as patent preparation and prosecution. Prior to joining the firm, Jin was a medicinal chemist for several pharmaceutical companies, including PTC Therapeutics, Johnson & Johnson Pharmaceutical Research and Development, and Aventis Pharmaceuticals. His experience encompassed a variety of sophisticated research areas pertaining to chemistry inventions and drug discovery. Jin received his PhD from University of Maryland at College Park and his J.D. from Rutgers University.

Lily Zou, PhD
CEO, Fosun Pharma USA

Lily Zou is CEO of Fosun Pharma USA, where she is responsible for growing Fosun Pharma’s US and Chinese markets via BD/investment activities as well as building operations in the US. Prior to joining Fosun Pharma, Lily was Executive Director, BD&L at Sandoz Inc., where she executed licensing, co-development, asset acquisition and divesture deals for generic, 505b2 and biosimilar products, and added over 30 products to Sandoz US portfolio with aggregated annual sales of over $700M. Prior to Sandoz, Lily worked at top management consulting firm (Bain), large phamas (Wyeth, Millennium), and smaller biotechs (ArQule, Coley) in various functions including BD&L, strategy, portfolio management and drug discovery.

Lily holds a Ph.D in Microbiology and Immunology from Cornell University, an MBA from MIT, and a B.S. in Biology from Beijing, University.
The names will be provided by the SAPA President Office and announced at the SAPA Annual Gala Dinner on September 30.
The SAPA Scholarship and Excellence in Education Program was established in 1999. The Scholarship is dedicated to recognize and support excellence on the part of outstanding high school students, and to encourage the finest high school graduates in the US to develop career in Life Sciences. Each scholarship awards a one-time fund of $1,000 towards tuition payment.

**Lillian Zhu**

Lillian Zhu graduated from Northwood High School in Irvine, California in 2017. In high school, Lillian was president of ClubMed and vice president of the California Scholarship Federation and Odyssey of the Mind clubs. Her Odyssey of the Mind team placed as finalists at the 2015 and 2016 TEAMS (Tests in Engineering Aptitude, Mathematics, and Sciences) national competitions. She is also a National AP Scholar and was awarded the prestigious Renaissance Award for achieving within the top 1% of diverse disciplines at her school. Aside from academics, Lillian was highly involved in Team HBV, an international non-profit organization that raises awareness for hepatitis B. In addition to serving as the Interchapter co-Chair in the Team HBV High School Board, Lillian led the Newsletter Outreach Committee, participated in the Website and Social Media Outreach Committees, and attended the Youth Leadership Conference at Stanford University. She also enjoys playing piano, tutoring her peers, and travelling with her family.

Fascinated by the life sciences, Lillian spent her sophomore summer at the Research in Biological Sciences program at the University of Chicago, where she learned microbiological wet-lab techniques and conducted a project on telomerase activity in mouse leukemia cells. The following summer, she was invited back to U. Chicago for a computational biology internship that involved running molecular dynamics simulations on the university supercomputer. Lillian is passionate about the interdisciplinary connections in biology and created short, animated biology lectures on YouTube as part of her endeavor to improve scientific communication. She is a current freshman pursuing biomedical engineering at Duke University.

**Brian Xia**

Brian Xia is a high school graduate from Canyon Crest Academy in San Diego, California in 2017. Brian was born in Huntington, a quaint Long Island town, where he lived for eight years. He then moved to San Diego, where he spent his formative years engaging in basic aging research. In addition to being a passionate athlete, Brian has accumulated thousands of hours studying aging and aging-related diseases under mentorships of three established scientists from both pharmaceutic and academic settings. Because of his remarkable dedication and groundbreaking work, Brian has contributed immensely to the aging field with multiple first-authorship publications, and his soon-to-be-published discovery of the first shared mechanism among aging and aging-related diseases. To his honor and recognition, Brian is currently drafting a book chapter upon invitation, and under consideration for joining the Reviewer Board of a peer-reviewed open access aging journal. These experiences have motivated him to pursue a life science related career.

A Regeneron Science Talent Search Scholar and National Merit Scholar, Brian is a current freshman with a joint Computer Science and Molecular Biology major at Massachusetts Institute of Technology.
The SAPA Graduate Travel Grant was established in 2014 to promote and encourage innovative research in the fields related to pharmaceutical and biotechnological sciences and to provide selected graduate students or postdocs a networking and learning opportunity to get to know the industry. The grant is given annually to two or more graduate students or postdocs who have conducted outstanding research in the field of life sciences and decides to pursue a career in pharmaceutical or biotech industry. Each Grant includes a one-time fund of $500 to be awarded to each of the selected Grant recipients for attending the SAPA annual conference in New Jersey, while waiving registration fees for attendance of the Conference. The Grant is open to any qualified graduate students and postdocs throughout the United States.

The SAPA Graduate Travel Grant in 2017 is sponsored by Hisun Pharmaceuticals USA, Inc. (a subsidiary of Zhejiang Hisun Pharmaceutical Co. Ltd., based in Princeton, New Jersey and committed to the development, manufacture and commercialization of pharmaceutical products for the US market place with a focus on APIs, Generics, Specialty and Animal Health Products, www.hisunusa.com).

The “2017 SAPA-Hisun Graduate Travel Grant” has been awarded to Hanzhou Feng, a graduate student in the Department of Pharmaceutics, Dequesne University, Pittsburgh, Pennsylvania; Weipeng Shen, a graduate student in the Department of Biomedical Engineering, State University of New York at Buffalo; and Robson Amaral, a graduate student in the School of Pharmaceutical Sciences of Ribeirao Preto (FCFRP), University of Sao Paulo, Brazil, and a visiting student in the Department of Biochemistry and Molecular Medicine, School of Medicine, University of California Davis.

Hanzhou Feng  Weipeng Shen  Robson Amaral
• A biotech/biopharma company based in Boston area
• Unique and fast antibody discovery platform
• Superior bispecific antibody technology
• Validated by blue chip pharma partners
• Expansion into China market
• Highly experienced management team
• World class Scientific Advisor Board

For more information: contact James Yang, PhD, President/CEO, Abpro-China
(cell) 5087457133, jyang@abpro-labs.com, or www.abpro-labs.com

6 Dimensions Capital

6 Dimensions Capital is formed through a merger of equals between WuXi Healthcare Ventures and Frontline BioVentures. The teams are highly complementary to each other. WuXi Healthcare Ventures has a clear advantage with its access to innovative startups in the US, and Frontline has a more established venture investment exposure in China. The merger creates a powerhouse to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific. The new investment team consists of 26 investment professionals, including 9 Partners and 7 Venture Partners.

As a global leader in R&D genomics services, GENEWIZ leads the way in providing superior data quality with unparalleled technical support to enable researchers around the world to advance their scientific discoveries faster than ever before.

Our customers at top-tier pharmaceutical, biotechnology, and academic institutions, as well as cutting-edge start-ups, rely on GENEWIZ's proprietary technologies for consistent, reliable, high-quality data, even on the most difficult projects. A full-service provider, GENEWIZ provides Sanger DNA sequencing, gene synthesis, molecular biology, high throughput/next generation sequencing, bioinformatics, and GLP regulatory services.

Today, GENEWIZ has the largest network of genomics laboratories around the world. Our customers are supported by major investments in state-of-the-art facilities, rigorous quality systems based on Good Laboratory Practice (GLP), and highly-qualified scientific teams. GENEWIZ also holds the ISO:9001:2008 Quality Management Certification, a voluntary international certification noting operational excellence and quality standards.
Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and pharmaceutical researchers.
ALEON PHARMA INTERNATIONAL, INC.

Aleon Pharma International, Inc. (Aleon) offers expert regulatory consulting and high quality clinical development solutions specifically tailored to each client’s individual requirements in pharmaceutical and biotech product development.

Our primary focus is to assist pharmaceutical and biotechnology companies in their new product development and post-marketing compliance in the United States and other countries. Aleon’s goal is to make the path to new drug approval more effective for its clients. Our company is driven by our commitment to quality solutions, scientific innovation, and continuous improvement.

Headquartered in Parsippany, New Jersey, the heartland of the pharma industry, and staffed by seasoned professionals, Aleon has provided effective strategies and product development solutions for our clients. Aleon’s team members are seasoned industry executives, with decades of experience in creating strategic solutions for clients in pharmaceutical and biotechnology industries. Because of this, we bring a tremendous amount of skill and value to our clients.

AllyChem Co., Ltd.

The largest diboron manufacturing base in the world

Founded in 2004, AllyChem, Dalian, China is a high-tech enterprise that is dedicated to providing pharmaceutical intermediates, organic electronic materials production and specialized services to pharmaceutical, fine chemical and electronic material companies from grams to multi-ton scale around the world. It specializes in organic boronic acid and boronic acid ester, and is a top producer of organic boronic acids in China and the largest diboron esters production base in the world.

Located in the Dagushan chemical industrial park of Jinzhou new district, AllyChem’s facilities cover more than 20000 square meters, including organic synthesis laboratory, analysis lab, kilo lab and production plant. Organic synthesis lab has 54 standard fume hoods. Analysis laboratory is equipped with Agilent GC/MS, Agilent HPLC and GC, and can undertake conventional chemical analysis. Together they cover 1000 square meters. Production plant, covering 6000 square meters, has nearly 70 reactors with size varying from 20L to 3000L. These reactors are made of 304 stainless steel, 316 L stainless steel, enamel glass or Teflon. AllyChem can run various types of synthesis reactions, including coupling reaction, asymmetric catalytic reaction, hydrogenation reaction, Grignard reaction, low (i.e., -80 °C) and high temperature as well as high pressure reaction. AllyChem is going to build a second production facility covering 70000 square meters, including GMP and fine chemical plant, starting next year and to be completed by 2020.

AllyChem has overall 130 employees; among them more than 25% are scientific or technical staff. Guided by a management team with extensive experience collaborating with overseas pharmaceutical and chemical companies, the company emphasizes innovation and commercialization of proprietary technology and owns many patents on technology to produce coupling reagents and chiral compounds. Over the years, AllyChem has developed over 600 synthesis processes, and hundreds of which can be manufactured in industrial scale. AllyChem can accelerate your research by providing inventory goods, customer synthesis, contract manufacturing and technical development.

Looking forward to being your valuable partner.

And welcome to join us, to be one of us.
ASCENDIA PHARMACEUTICALS
“Aspiring for Better Medicine”

Ascendia Pharmaceuticals, founded in 2012, is a privately-owned, specialty pharmaceutical company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates. We specialize in creating formulation solutions for poorly-water soluble molecules and other challenging pharmaceutical development projects. Using our suite of nano-particle technologies, we can assess the feasibility of a broad array of formulation options in order to improve a drug's bioavailability. We execute rapid, comprehensive, and cost-effective programs for our clients. Our technologies include nano-emulsions, amorphous solid dispersions, and production of nano-crystals. Ascendia provides development and testing services - from discovery-stage molecules to life-cycle-management projects - creating formulation solutions with enhanced biopharmaceutical properties suitable for clinical scale-up. Ascendia formulates products for injectable, transdermal, ophthalmic delivery, and both immediate-release and controlled-release products for oral administration. Ascendia offers drug development services that encompass preclinical development, pre-formulation development, clinical formulation development, analytical/bio-analytical development, and modeling & simulation of small and biological molecules. Ascendia has a proprietary pipeline of pharmaceutical product candidates, led by ASC-002, a novel, injectable form of the anti-thrombotic drug Clopidogrel and ASD-004, a novel clear eye drop nano-emulsion of cyclosporine for dry eyes. Ascendia Pharma is headquartered in North Brunswick, NJ, with a state-of-the-art pharmaceutical research located at the Commercialization Center of Innovative Technology (CCIT), and is also building a 9,000-square foot formulation research and development facility in Xiamen, China.
For more information visit us at www.ascendiapharma.com or contact:
Jim Huang, CEO/CSO, j.huang@ascendiapharma.com

AustarPharma LLC

AustarPharma is a rapidly growing technology based pharmaceutical company located in Edison, NJ. We are engaged in the development, manufacturing, and sales and marketing of generic and other pharmaceutical products developed internally or by our worldwide strategic co-development partners. AustarPharma also continues to offer our clients integrated contract services that provide turn-key solutions ranging from early development to cGMP manufacturing and product sales.

AustarPharma was founded as a research and development company, specializing in drug delivery technologies in 2004 by Ron Liu, Ph.D., MBA, President and CEO. That strength and commitment has been very strong and has become even stronger today. We welcome the opportunity to help our partners and clients to define, plan and execute their product development strategies and projects. Our cGMP development, manufacturing and testing facility was acquired from Abbott Laboratories in 2009. It has been inspected by the FDA and EU Health Authorities and it is equipped to handle controlled substances (CII-V). In 2015, we acquired a new 30,000 sq.ft facility.

AustarPharma has partnered with more than 10 US biotech and pharmaceutical companies including some of the top 10 companies as well as more than 20 overseas major pharmaceutical companies to co-develop strategic and high sales potential pharmaceutical products. Our pipeline is now rich with more than 50 ANDA drug products, among them 6 products approved, around 20 products pending approval, and around 30 funded toward submission to FDA. Our approved products have been sold in the US market since 2011. We welcome you to contact us to discuss career opportunities, potential product development and/or sales and marketing partnership opportunities.
WE SEQUENCE, YOU DISCOVER

From Biomarker discovery and validation to Companion Diagnostics, BGI is the Pharma Services Organization of choice for 18 of the top-20 Pharma companies.

Pharma Services
BGI’s Experience and Network:
✓ Global partnership experience
✓ Quality and Regulatory compliance
✓ Access to patients in China
✓ Access to government and clinical resources in China
✓ Validated cancer panels

Sequencing Services
Global NGS Services:
✓ Genomics
✓ Transcriptomics
✓ Epigenomics
✓ Immune Repertoire
✓ Bioinformatics

To learn more about how BGI’s experience can put your Drug Discovery projects in overdrive, come talk to us at our booth, or visit our web site www.bgi.com

China Medical City
Professional Bio-medical Hi-tech Park in China

China Medical City is located in Taizhou, an important city in the Yangtze River Delta in Jiangsu Province. The Planned core area of CMC is 30 square km², integrating functional zones of R&D, manufacturing, exhibition and trade, healthcare service, advanced education, administration and related functional facilities. CMC is the first national level hitech zone focusing on biomedical field which is co-built by the Ministry of Science and Technology, National Health and Family Planning Commission, CFDA, State Administration of Traditional Chinese Medicine and Jiangsu Provincial Government. We are committed to build CMC into the largest bio-medical base with the most integrated industrial chain in China.

Website: http://www.cmcnews.net/
Contact: Ray WANG, PhD
Mobile: 86-15261006755
Tel:86-523-86200142
Email: wangruikmc@126.com
WeChat: 13581882321
**Crystal Pharmatech**

Founded in July 2010, Crystal Pharmatech is a global, technology-driven research organization with labs in Suzhou, China and Cranbury, NJ with combined over 65,000 sq. ft. and over 100 employees. Our research focuses on crystal form screening/selection, crystallization development and add-on CMC services that guide pharmaceutical companies to develop new drugs efficiently and effectively. With a leading platform in solid form research and pre-formulation, Crystal Pharmatech has built successful business relationships with over 300 pharmaceutical companies with a primary focus of progressing compounds from candidate selection to IND application.

晶云药物成立于 2010 年，总部在苏州工业园区生物纳米园，分部设立在北京及美国新泽西州，是中国首家专注于药物晶型研发和产业化的公司。晶云通过建立的国内首个药物晶型研发中心，以晶型研究为起点深入纵向发展，推出新药 CMC 服务，帮助全球各制药公司加速新药研发进程，提早在中美等地区提交新药申请并上市。晶云领导团队成员过去在美国 Merck, BMS, Roche, J&J 等制药公司，直接负责和从事药物晶型研究，结晶工艺开发以及 CMC 研发，共积累了在该领域 100 多年的研发和管理经验。在过去 7 年，晶云团队成员凭借专业的服务和快速的反应，已与全球超过 300 家制药企业建立合作，为 1000 多个新药候选化合物提供了药物晶型研发的专业技术方案。

**Disha Pharmaceutical Group**

Disha Pharmaceutical Group which has 10 subsidiaries and has more than 4,000 employees and a total asset value of over RMB 835 million (approximately US$129 million) is situated in Weihai City, a picturesque coastal city in China. Disha has four production bases, including western medicine preparation, active pharmaceutical ingredients, chinese traditional patent medicine and protective food.

So far, through 18 years’ development, Disha Pharmaceutical Group covers a manufacturing area of 140,000 square meters including High standard preparation workshop and API workshop with an area of 20,000 square meters that both obtained the cGMP Certificate. It currently produces more than 50 types of medical products with more than 100 specifications, which are famous in overcoming Diabetes mellitus, Hypertension, Hypopepsia and Inflammation. Some kinds of products gained Shandong Famous Product more than once and in 2011 Disha Group was grant with China well-know trademark.

Ranking in the China's pharmaceutical industry Top 100, in 2010 the Disha Pharmaceutical Group achieved sales revenue of RMB 1.69 billion and aim at that sales revenue will reach RMB 3 billion in 2013 and become national large-scale Pharmaceutical group in 2015 with 10 billion sales proceeds.

Adhering to the concept of people-oriented concept, Disha Pharmaceutical Group in exploring a scientific and healthy development model. Disha is well-positioned to continuing serving the medical community and improve people’s health for generations to come.
Fox Rothschild is proud to support the Sino-American Pharmaceutical Professionals Association.
Congratulations!!!

Fox Rothschild LLP
ATTORNEYS AT LAW

110 Year History | 800 Attorneys | 23 Offices Nationwide

Wansheng Jerry Liu, Ph.D., J.D., Partner
609.844.3037 | wliu@foxrothschild.com


Frontage is a full service CRO that collaborates with pharmaceutical and biotech companies, helping them bring promising drug candidates to market.

We are committed to forging a partnership with our clients in order to provide real solutions to their drug development challenges.

Our experts in analytical testing, product development, DMPK, bioanalysis, clinical, and biometrics will work with you to turn services into solutions.
Gene Universal, located in Delaware USA, is a pioneer in the field of gene synthesis and synthetic biology. As a leading company in genomics research and applied biological technology, and with our strong technical force, unparalleled customized service and fast delivery time, we are aiming to provide more cost-effective service and product to accelerate the global research in drug discovery, biology optimization, food and agriculture, etc.

Gene Universal is specialized in the area of genetic engineering, biosystem engineering and synthetic biology. By providing our industrialized and highly intensive gene synthesis platform, we could deliver both normal and complex genes in short promised time. We have also developed sophisticated software programs to design and optimize complex gene libraries and genetic systems, with these bioinformatics tools and our high-efficiency production management systems, we are able to satisfy scientific researchers with high-efficient, low-cost, and large-scale synthetic genes and genome DNA.

Meanwhile, based on our five cutting-edge expression systems: Bacterial Expression, Mammalian Expression (293 & CHO), Yeast Expression, Insect Expression and Bacillus subtilis Expression system, we have become the one-stop vendor for your gene synthesis, protein expression, and antibody production services.

Our goal is to become the global leader in DNA synthesis and synthetic area, and to achieve the prosperous prospects of making research in life science more efficient and lower cost.
Hisun Pharmaceuticals USA, Inc

Hisun USA Family
As the wholly owned subsidiary of Zhejiang Hisun Group, Hisun Pharmaceuticals USA not only enjoys its strong support from China, but also has the flexibility to build and develop our business in the US.

We are a young and open-minded company which is always seeking for potential partners and opportunities.

Our Princeton site now operates business including sales & marketing, clinical operations, logistics and regulatory affairs, etc.

Now We Are Recruiting... We have several exciting positions available and we are seeking enthusiastic professionals to join us

Please come to our booth for more details.

Contact Us
609-275-5055
hisunHR@hisunusa.com
www.hisunusa.com

Zhejiang Huahai Pharmaceutical Co., Ltd. was initially founded in 1989, and the company's stock was successfully listed in Shanghai Stock Exchange in March, 2003.

Huahai Pharmaceutical, a large scaled modern pharmaceutical group that integrates formulations, APIs(Active Pharmaceutical Ingredients) and intermediates, is developing both domestic and international markets, and performing parallel development of science, industry and commerce. With a total asset of 1,900 million yuan, the company has 11 branches (subsidiaries) in the United States, Shanghai, Hangzhou, and Linhai. It occupies an area of 800,000 square meters, and has a staff of 3400. The company is entitled as National Key Hi-tech Enterprise, National Pilot Enterprise of Innovation, and China's top 500 private enterprises, and possesses a "State Certified Enterprise Technology Center".

Huahai Pharmaceutical is the largest supplier of pril products worldwide, with the annual production capacities of its dominating products "captopril" and "enalapril" both ranking first in the world. It is also the only manufacturer in the world that can realize commercial production of captopril, enalapril and lisinopril at the same time, enjoying the reputation of a "Pril Specialist". The pril drugs of the company boast absolute advantages in international markets in terms of production scale, product quality, technological skills and R&D.

The company's workshops of formulation are designed in strict compliance with the international cGMP standard, where the most advanced automatic pharmaceutical production equipment in the world was introduced. We are the first pharmaceutical company in China that has passed USA FDA approval.
Logan Instruments

Logan Instruments is a lab instrument manufacturer with a focus on dissolution, physical, and transdermal/topical testing systems. It prides itself on three core concepts that have been the pillars of the organization since 1990. First, Logan’s INNOVATION is second to none in its industry. R & D never rests inside the walls of Logan’s facility. It starts with listening to its current customers, as well as prospective ones. Logan is always adapting to a marketplace that is constantly evolving. Logan remains committed to bringing new ideas and equipment to the industry with the help of its entire team. New products that they have recently released are:

1. **3-Speed Dissolution System with a camera system for each vessel.** A unique product to the marketplace that one can only find at Logan Instruments.

2. **Suspension System and USP IV.** This system acts as two systems in one. Excellent for labs where space is a concern.

3. **Coming very soon!** A cultured skin to be purchased with a company’s Transdermal System order. Logan’s commitment to a customer first mentality combined with the ever-expanding transdermal and topical marketplace made this a space that Logan feels is ready to explode. The second is QUALITY and it all starts with the individuals that they hire. Despite their employees often working separately in their own departments, they are all working toward the same goal of delivering a product to their customers they can be very proud of. Logan has maintained its standing as an ISO certified company for many years. Finally, SERVICE must play a vital role in maintaining relationships with existing customers. A finished product is just the beginning in Logan’s eyes. The customer service team remains vigilant with its current customers. They are constantly seeking feedback, so that they can enhance the experience of working with Logan.

To conclude, Logan Instruments has delivered and will look forward to keep delivering on these principles for decades to come. When looking for your lab instrument testing system, look no further than Logan.
MilliporeSigma is the U.S. life science business of Merck KGaA, Darmstadt, Germany. With 19,000 employees and 72 manufacturing sites worldwide, MilliporeSigma’s portfolio spans more than 300,000 products enabling scientific discovery. MilliporeSigma has customers in life science companies, university and government institutions, hospitals and industry. More than 1 million scientists and technologists use its products. The company is committed to solving the toughest problems in life science by collaborating with the global scientific community. For more information, visit www.emdmillipore.com and www.sigma-aldrich.com.

Website:
Both the emdmillipore.com and sigma-aldrich.com websites should be indicated or for 1 website please use www.milliporesigma.com

Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine, established in 1970 and headquartered in Jiangsu Province, is China’s front-runner in innovative medicine and has the largest R&D center of antineoplastics and surgical medicine. Hengrui Medicine has established brand advantages in the field of antineoplastics, surgical medicine, contrast agents, cardiovascular and endocrine medicines. All across the world today, there are over 12,000 employees at Hengrui Medicine. With a commitment to produce high quality medicines and help patients have access to better medical resources, Hengrui Medicine has innovative R&D centers and clinical divisions in New Jersey (USA), Lianyungang, Shanghai, Chengdu, Suzhou, Nanjing, as well as Japan and Australia.
Zhuhai Rundu Pharmaceutical Co., Ltd is a high-technology enterprise, which is specialized in R&D, Production and sales of API and Formulation. The company totally has more than one thousand employees and covers an area of 90,000 ㎡. The company located in Zhuhai which production range includes Intermediate, API, Pellet, Tablet, Capsule, Injection and covers the fields of cardiovascular system, digestive system, anesthesia, respiratory tract, anti-infection and anti-malaria. With the development of the company, we’ll set up a wholly owned subsidiary company in New Jersey USA which is specialized in R&D of formulation. We recruit the following positions and invite you to join us.

**Director-Formulation R&D**
Responsibility: Direct and manage formulation R&D team to develop the products of sustained release oral solid dosage form.

**Director-Analytical Development**
Responsibility: Direct and manage analysis team to develop and validate the analytic methods of sustained release oral solid dosage form products. Conduct stability studies and formulation testing etc.

**Formulation R&D Scientist**
Responsibility: Develop the products of sustained release oral solid dosage form including formulation & process development, technology transfer, registered batch manufacturing, ANDA submission etc.

**Analytical Scientist**
Responsibility: Development and validation of analytical methods of sustained release oral solid dosage form products, conduct stability studies and formulation testing etc.

**Regulatory Affairs Specialist**
Responsibility: Responsible for the document submission and following in the regulatory market. Update the latest international regulation to support company strategic decision.

Contact: Angela Wang;
Tel: +86 0756 7630722; +86 13923373299; Email: wyc@rdpharma.cn; Website: www.rdpharma.cn
Simcere Pharmaceutical Group

Founded in 1995, Simcere is a leader in developing, manufacturing and marketing of innovative medicines and branded generics in China focusing on oncology, neurology, cardiovascular & metabolic diseases, inflammation and infectious diseases.

Simcere currently operates one R&D center, two sale and marketing subsidiaries and four manufacturing facilities. Simcere has advanced marketing and sales capabilities, maintains stable and harmonious cooperation with hospitals, distributors and retail pharmacies. It currently has approximately 3,000 employees in China.

Simcere R&D center was established in 2003 and has grown to over 200 scientists. Simcere has been investing 6-11% of the company's revenue into R&D annually. Ten IND has been filed to CFDA since 2010. In 2015, Simcere’s translational medicine and innovative drug R&D platform has been accredited as State Key Laboratory by the National Ministry of Science and Technology. It was elected as ‘Top 100 Enterprises in the PRC Pharmaceutical Industry’ and ‘Top 10 Innovation Pharmaceutical Companies in China’ for consecutive years.

Having 4 GMP facilities, Simcere now is following cGMP and EUGMP to transform Nanjing and Hainan facilities to reach international standards. In additional, our montmorillonite powder raw material and preparations which made from Hainan facility successfully passed EUGMP certification and were exported to Europe since 2009.

Simcere also actively pursues cross-border partnership to sourcing global innovation and brands to China. Our partners included BMS, Dalichi Sankyo, GSK, and Appexigen, etc. Meanwhile, together with BioSciKin, which is a biotechnology platform for precision medicine innovation, Simcere has participated in 8 prestigious venture capitals globally, including Ally Bridge Group, Cormorant asset etc. By the end of 2016, Simcere has invested over 1 billion US $ to accelerate international business development.

Simcere has kept in mind the enterprise mission of ‘hunting for and providing more valid drugs to patients.'

TC Scientific is a chemistry contract research company located in Edmonton, Alberta, Canada. Founded in 2009, TC Scientific has provided high-quality synthetic chemistry services to a variety of pharmaceutical, biotechnological, agrochemical, academic, biosensor, and nanomedicine-based companies.

TC Scientific boasts a highly experienced, all-PhD staff. Fields of expertise include medicinal chemistry (compound and route design); process chemistry route design; nucleoside, carbohydrate, heterocyclic, and stable isotope chemistry; chiral synthesis and purification; and multi-step complex synthesis on scales ranging from 1mg to 5Kg. Full-Time Equivalent (FTE) and custom synthesis services are also available. In addition, TC Scientific is on schedule to provide Current Good Manufacturing Practices (cGMP) certification for Active Pharmaceutical Ingredient (API) production in early 2018.

The cornerstones of TC Scientific’s offerings are competitive prices, high-quality results, and a strict adherence to client confidentiality. For a price quote on any of your chemistry needs, please contact Dr. John Yao, CEO, TC Scientific, Inc., jjyao@tcscientific.com, 1-888-577-0258.
WuXi AppTec Laboratory Testing Division (LTD) provides a comprehensive and integrated testing platform for drug development. With operations in both China and the U.S., LTD provides services and solutions in analytical chemistry, *in vivo* pharmacology, drug metabolism and pharmacokinetics, bioanalysis, toxicology, clinical testing and customized antibody and reagent preparation.

Recently, the success of Investigational New Drug (IND) application is a milestone achievement of early stage drug development. The fierce competition and increasing complexity of drug development process are demanding an open platform with multi-discipline integration, more economic and efficient delivery. WuXi AppTec IND program (WIND) is our approach to account for these challenges. The service coverage of WIND spans the whole spectrum of preclinical drug development, from candidate nomination all the way to safety assessment. The comprehensive service portfolio includes API manufacturing of both chemical drugs and therapeutic antibodies, formulation development and clinical supply, analytical chemistry, pharmacology, bioanalysis, drug metabolism and pharmacokinetics, as well as toxicology. Along with these service modules, the professional project management team is dedicating to internal and external communication, logistics and schedule coordination to ensure the cost-efficient, time-saving project delivery. The highly customizable WIND is offering flexible business approaches, either a la carte services or bundled as an integrated IND package, empowering anyone of different needs to develop their pipelines to IND in an one-stop shop approach.

Please contact us for any request: info_ltd@wuxiapptec.com

**WuXi Biologics**

WuXi Biologics (2269.HK), a Hong Kong-listed company, is a global leading biologics services provider that offers comprehensive, integrated and highly customizable services. The company offers multinational pharmaceutical and biotechnological companies in the world end-to-end solutions empowering anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing. Our services are designed to help our worldwide clients shorten the discovery and development time and lower the cost of biologics.

WuXi Biologics has over 2000 employees, including more than 200 overseas returnees and scientists with advanced degrees and work experience abroad. We have rich experience in antibody development, manufacturing, quality control, preclinical research and registration in European and American markets. All members of senior management team have worked at the forefront of the biologics industry with an average of over 20 years of industry experience in their fields of expertise, enabling us create a world-class pharmaceutical biologics discovery, development and manufacturing team.

We have a diversified customer base. Most of our customers are pharmaceutical and biotechnology companies, including many renowned industry players, such as AstraZeneca UK, Ltd., Genentech, Inc., TESARO, Inc., Momenta Pharmaceuticals, Inc., Amicus Therapeutics Inc., Janssen Research & Development, LLC (a Johnson & Johnson company), TaiMed Biologics Inc., OPKO Biologics Ltd., CStone Pharmaceuticals, Harbin Gloria Pharmaceuticals Co., Ltd., Hualan Genetic Engineering Co., Ltd., Zhejiang Medicine Co., Ltd. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. As of the Latest Practicable Date, we had worked with 12 out of the 20 largest pharmaceutical companies in the world as measured by their respective pharmaceutical sales in 2016. We had 334 on-going projects, 189 of which require us to provide services across different stages of the biologics development process, namely, integrated projects.

In August 2017, WuXi Biologics completed China’s first FDA pre-license inspection for ibalizumab, making the inspected facility to be the first commercial cGMP biologics manufacturing facilities in China if ibalizumab is approved. This continues to reinforce the strong commitment to quality WuXi Biologics has made to its global client base and enable China as the important global biologics outsourcing player in the world.

For more information about WuXi Biologics, please refer to WeChat:
Chengdu

World’s Fastest Growing City in the Next Decade
— Forbes 2010

The Most Livable City in China
— Economist, 2012

Top 10 Entrepreneurial Cities in China
— Fortune, 2015

Ranked 3rd among Asia’s Best-Performing Cities
— Milken Institute, 2014

2017 SAPA Annual Conference
SAPA Media Partners

www.sapaweb.org • SAPA 25th Annual Conference • September 29 & 30, 2017 • 63
Sino-American Pharmaceutical Professionals Association

PO Box 282
Nanuet, NY 10954, USA

http://www.sapaweb.org
http://weibo.com/sapaweb

WeChat: